 
 
 
Official Title  
 Home Use of MD -Logic Automated Insulin Delivery System:  
Safety and Efficacy  
 
Brief Title: Fuzzy Logic Automated Insulin Regulation (FLAIR)  
NCT 03040414 
Date: March 17, 2020 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 1 OF 74 
 Signature [CONTACT_3490]  1 
 2 
FLAIR - Fuzzy Logic Automated Insulin Regulation:  3 
A Crossover Study Comparing Two Automated Insulin Delivery System 4 
Algorithms (PID vs. PID + Fuzzy Logic) in Individuals with Type 1 Diabetes  5 
 6 
IDE Sponsor: Jaeb Center for Health Research  7 
 8 
Version Number: v 7.1 9 
 10 
17 Mar 2020  11 
 12 
 
JCHR Protocol Director, Name/degree  Judy Sibayan, MPH, CCRP  
Signature/Date   
 
Clinical Lead Investigator  and Protocol 
Chair , Name/degree  Richard M. Bergenstal, MD  
Signature/Date   
 
Protocol Chair , Name/degree  Moshe Phillip , MD  
Signature/Date   
 
Medical Monitor, Name/degree  Roy W. Beck, MD, PhD  
Signature/Date   
 13 
 14 
  15 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 2 OF 74 
 FLAIR - Fuzzy Logic Automated Insulin Regulation:  16 
A Crossover Study Comparing Two Automated Insulin Delivery System 17 
Algorithms (PID vs. PID + Fuzzy Logic) in Individuals with Type 1 Diabetes  18 
 19 
IDE Sponsor: Jaeb Center for Health Research  20 
 21 
Version Number: v 7.[ADDRESS_1185082] M. Bergenstal, MD  
Institution Name  [CONTACT_852342], Health Partners Institute  
Name, Degree  Moshe Phillip, MD  
Institution Name  [CONTACT_852343]. National Center for Childhood Diabetes. 
Schneider Children's Medical Center of Israel  
Central Administration  
International Diabetes Center, Health Partners Institute  
JCHR Coordinating Center Director  
Name, degree  Judy Sibayan, MPH, CCRP  
Institution Name  [CONTACT_852344], degree  Roy W. Beck, MD, PhD  
Institution Name  [CONTACT_352741]  
  [ADDRESS_1185083] OF ABBREVIATIONS  ................................ ................................ ................................ ............................  8 32 
SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_66674]  ................................ ..............................  9 33 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  10 34 
SCHEMATIC OF STUDY DESIGN  ................................ ................................ ................................ ................  15 35 
SCHEDULE OF STUDY VISITS AND PROCEDURES  ................................ ................................ .....................  16 36 
 BACKGROUND INFORMATION  ................................ ................................ .............................  18 37 
 Introduction  ................................ ................................ ................................ ................................ ....... 18 38 
 Background: Studies descriptions below include data from PID, MD -Logic, 39 
and the combined algorithms:  ................................ ................................ ................................ ..............  18 40 
 Pre-Clinical Testing of MD -Logic Algorithms  ................................ ................................ ...........  19 41 
 Clinical Studies using MD -Logic Systems  ................................ ................................ ..................  19 42 
 Medtronic HCL Studies  ................................ ................................ ................................ ...............  21 43 
 Integrated Advanced HCL System In -Silico Testing  ................................ ................................ .. 24 44 
 Further Studies and Updates to the Advanced HCL System:  ................................ ......................  25 45 
 Rationale  ................................ ................................ ................................ ................................ ............  27 46 
 Automated Insulin De livery System Description  ................................ ................................ ..............  28 47 
 Potential Risks and Benefits of the Investigational Device  ................................ ...............................  29 48 
 Risk Assessment  ................................ ................................ ................................ ................................  35 49 
 Known Potential Benefits  ................................ ................................ ................................ ..................  35 50 
 Genera l Considerations ................................ ................................ ................................ ......................  35 51 
 STUDY ENROLLMENT AND SCREENING  ................................ ................................ ..............  36 52 
 Participant Recruitment and Enrollment  ................................ ................................ ...........................  36 53 
 Participant Inclusion Criteria  ................................ ................................ ................................ .............  37 54 
 Participant Exclusion Criteria  ................................ ................................ ................................ ............  38 55 
 Screening Procedures  ................................ ................................ ................................ ........................  38 56 
 Data Collection and Testing  ................................ ................................ ................................ ........  39 57 
 Questionnaires  ................................ ................................ ................................ .............................  39 58 
 RUN-IN PHASE  ................................ ................................ ................................ ......................  40 59 
 Introduction  ................................ ................................ ................................ ................................ ....... 40 60 
 Pump Run -In – 670G  3.0 HCL  ................................ ................................ ................................ ..........  40 61 
 Pump+CGM Run -In – 670G 3.0 HCL + Guardian Sensor (3)  ................................ ..........................  [ADDRESS_1185084] Schedule during Study Periods 1 and 2  ................................ ...............  44 75 
 Procedures During Study Periods  ................................ ................................ ................................  44 76 
[IP_ADDRESS] Procedures performed during each contact  ................................ ................................ .........  44 77 
[IP_ADDRESS] Procedures performed during each follow -up visit  ................................ .............................  45 78 
[IP_ADDRESS] Setpoint adjustments during 670G 4.0 AHCL use  ................................ ..............................  45 79 
 Device Data Uploads Duri ng the Crossover Trial  ................................ ................................ ....... 46 80 
 Early Termination Visit  ................................ ................................ ................................ ...............  46 81 
 Unscheduled Visits  ................................ ................................ ................................ ......................  46 82 
 STUDY DEVICES AND SAFETY  ................................ ................................ ..............................  47 83 
 Description of the Study Devices  ................................ ................................ ................................ ...... 47 84 
 Insulin Pumps  ................................ ................................ ................................ ..............................  47 85 
 Continuous G lucose Monitoring  ................................ ................................ ................................ . 47 86 
 Blood Glucose Meter and Strips  ................................ ................................ ................................ .. 47 87 
 Ketone Meter and Strips  ................................ ................................ ................................ ..............  47 88 
 Study Device Accountability Procedures  ................................ ................................ ..........................  47 89 
 Blood Glucose Meter Testing  ................................ ................................ ................................ ...... 48 90 
 Blood Ketone Testing  ................................ ................................ ................................ ..................  48 91 
 Safety Measures  ................................ ................................ ................................ ................................ . 48 92 
 CGM Calibration  ................................ ................................ ................................ .........................  48 93 
 Pump Failure  ................................ ................................ ................................ ...............................  48 94 
 Hypoglycemia Threshold Alarm and Safety Protocol  ................................ ................................ . 48 95 
 Hyperglycemia Threshold Alarm and Safety Protocol  ................................ ................................  49 96 
 Safety Measures Specific to AID system use  ................................ ................................ ..............  49 97 
[IP_ADDRESS] Insulin Dosing  ................................ ................................ ................................ .....................  49 98 
 Safety Measures for Open -Loop (Manual Mode) CGM Use  ................................ ......................  49 99 
[IP_ADDRESS] Hypoglycemia Safety Protocol  ................................ ................................ ...........................  49 100 
[IP_ADDRESS] Hyperglycemia Safety Protocol  ................................ ................................ ..........................  49 101 
 LABORATORY TESTING AND QUESTIONNAIRES  ................................ ................................ . 50 102 
 Laboratory Testing  ................................ ................................ ................................ ............................  50 103 
 Questionnaires  ................................ ................................ ................................ ................................ ... 50 104 
 ADVERSE EVENTS , DEVICE ISSUES , AND STOPPI[INVESTIGATOR_16442]  ................................ ..............  51 105 
 Adverse Events  ................................ ................................ ................................ ................................ .. 51 106 
 Definitions  ................................ ................................ ................................ ................................ ... 51 107 
 Reportable Adv erse Events  ................................ ................................ ................................ .........  52 108 
[IP_ADDRESS] Hypoglycemic Events  ................................ ................................ ................................ .........  52 109 
[IP_ADDRESS] Hyperglycemic/Ketotic Events  ................................ ................................ ...........................  52 110 
 Relationship of Adverse Event to Study Device  ................................ ................................ .........  53 111 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 6 OF 74 
 
 Intensity of Adverse Event  ................................ ................................ ................................ ..........  53 112 
 Coding of Adverse Events  ................................ ................................ ................................ ...........  54 113 
 Outcome of Adverse Event  ................................ ................................ ................................ .........  54 114 
 Reportable Device Issues  ................................ ................................ ................................ ...................  55 115 
 Pregnancy Reporting  ................................ ................................ ................................ .........................  55 116 
 Timing of Event Reporting  ................................ ................................ ................................ ................  55 117 
 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ...............................  56 118 
 Participant Discontinuation of Investigational Device  ................................ ................................  56 119 
 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  ................................ ................................ ..... 56 120 
 Independent Safety Oversight  ................................ ................................ ................................ ...........  57 121 
 MISCELLANEOUS CONSIDERATIONS  ................................ ................................ ...................  58 122 
 Drugs Used as Part of the Protocol  ................................ ................................ ................................ .... 58 123 
 Collection of Medical Conditions and Medications  ................................ ................................ ..........  58 124 
 Prohibited Medications, Treatments, and Procedures  ................................ ................................ ....... 58 125 
 Participant Compensation  ................................ ................................ ................................ ..................  58 126 
 Participant Withdrawal  ................................ ................................ ................................ ......................  58 127 
 Confiden tiality  ................................ ................................ ................................ ................................ ... 59 128 
 STATISTICAL CONSIDERATIONS  ................................ ................................ ........................  60 129 
 Statistical and Analytical Plans  ................................ ................................ ................................ ....... 60 130 
 Statistical Hypotheses  ................................ ................................ ................................ ......................  60 131 
 Sample Size  ................................ ................................ ................................ ................................ ..... 60 132 
 Outcome Measures  ................................ ................................ ................................ ..........................  61 133 
 Analysis Cohorts ................................ ................................ ................................ ..............................  62 134 
 Analysis of  the Primary Efficacy Endpoints  ................................ ................................ ...................  62 135 
 Analysis of the Secondary Endpoints  ................................ ................................ ..............................  64 136 
 Safety Analyses  ................................ ................................ ................................ ...............................  65 137 
 Adherence and Retention Analyses  ................................ ................................ ................................ . 65 138 
 Baseline Descriptive Statistics  ................................ ................................ ................................ ....... 65 139 
 Planned Interim Analyses  ................................ ................................ ................................ ..............  65 140 
 Sub-Group Analyses  ................................ ................................ ................................ ......................  66 141 
 Multiple Comparison/Multiplicity  ................................ ................................ ................................ . 66 142 
 Additional Tabulations and Analyses  ................................ ................................ ............................  66 143 
 Device Issues and Tabulations  ................................ ................................ ................................  66 144 
 Analysis of Quality of Life Data  ................................ ................................ .............................  67 145 
 DATA COLLECTION AND MONITORING  ................................ ................................ ............  68 146 
 Case Report Forms and Device Data  ................................ ................................ ...............................  68 147 
 Study Records Retention  ................................ ................................ ................................ .................  68 148 
 Quality Assurance and Monitoring  ................................ ................................ ................................ .. 68 149 
 Protocol Deviations  ................................ ................................ ................................ .........................  69 150 
 ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ................................ ............................  [ADDRESS_1185085] (IRB) (or Ethics Committee (EC))  ................................ ......................  [ADDRESS_1185086] of Abbreviations  160 
 161 
 162 
 163 ABBREVIATION  DEFINITION  
AID Automated Insulin Delivery  
AHCL  Advanced Hybrid Closed -Loop  
AP Artificial Pancreas  
ATTD  Advanced Technologies & Treatments for Diabetes  
AUC  Area Under the Curve  
BG Blood Glucose  
BGM  Blood Glucose Meter  
CRF  Case Report Form  
CGM  Continuous Glucose Monitoring  
CI Confidence Interval  
CLC  Closed -Loop Control  
CSII  Continuous Subcutaneous Insulin Infusion  
DKA  Diabetic Ketoacidosis  
DSMB  Data and Safety Monitoring Board  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HCL  Hybrid Closed Loop  
ID Identification  
IDE Investigational Device Exemption  
IOB Insulin -on-Board  
IQR Interquartile Range  
NIH National Institutes of Health  
PID Proportional, Integral, and Derivative  
PLGS  Predictive Low Glucose Suspend  
POC  Point -of-Care 
QA Quality Assurance  
QC Quality Control  
QOL  Quality of Life  
RCT  Randomized Controlled/Clinical Trial  
RMB  Risk-Based Monitoring  
SADE  Serious Adverse Device Event  
SAE  Serious Adverse Event  
SAP Sensor -Augmented Pump  
SD Standard Deviation  
SH Severe Hypoglycemia  
SMBG  Self-Monitoring of Blood Glucose  
TDI Total Daily Insulin  
UADE  Unanticipated Adverse Device Effect  
UI User Interface  
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 9 OF 74 
 Site Principal Investigator [INVESTIGATOR_666126]  164 
Protocol Title:  FLAIR - Fuzzy Logic Automated Insulin Regulation:  A Crossover Study 165 
Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in 166 
Individuals with Type 1 Diabetes  167 
 168 
Protocol Version/Date:  7.1/ March 17, [ADDRESS_1185087] read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 171 
my duties include ensuring the safety of the study participants enrolled under my supervision and 172 
providing the Jaeb Center for Health Research, which serves as the Coordinating Center for the 173 
protocol, with complete and timely  information, as outlined in the protocol.  It is understood that 174 
all information pertaining to the study will be held strictly confidential and that this 175 
confidentiality requirement applies to all study staff at this site.  176 
 177 
This trial will be carried out i n accordance with ICH E6 Good Clinical Practice (GCP) and as 178 
required by [CONTACT_716] (use applicable regulations depending on study location and sponsor 179 
requirements; examples follow): [LOCATION_002] (US) Code of Federal Regulations (CFR) 180 
applicable to cl inical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 181 
312, and/or 21 CFR Part 812).  182 
 183 
For the  outside of US  sites, the trial will be carried out in accordance with ICH E6 Good Clinical 184 
Practice (GCP), the Declaration of Helsinki, and s pecific regulations applicable to the countries [ADDRESS_1185088] (IRB), or other approved Ethics Committee, except where necessary [ADDRESS_1185089](s) to the trial participants.  191 
 192 
All key personnel (all individuals responsible for the design and conduct of this trial) have [ADDRESS_1185090] of this study are informed about 195 
their obligations in meeting the above commitments.  196 
 197 
Investigator’s Signature __________________________________  Date: _____ / _____ / _____  198 
 dd mon yyyy  199 
Investigator’s Name: ____________________________________  200 
 201 
Site Name/Number: _____________________________________  202 
 203 
  204 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 10 OF 74 
 Protocol Summary  205 
PARTICIPANT 
AREA  DESCRIPTION  
Title  A Crossover Study Comparing Two Automated Insulin Delivery System 
Algorithms (PID vs. PID + Fuzzy Logic) in Individuals with Type 1 
Diabetes  
(FLAIR - Fuzzy Logic Automated Insulin Regulation)  
Précis  A randomized crossover trial will compare the efficacy and safety of an 
automated insulin delivery (AID) system with a proportional -integral -
derivative (PID) algorithm versus an automatic insulin delivery (AID) system 
with a PID algorithm enhanced with a F uzzy Logic algorithm.  
Investigational 
Device  The Minimed 670G 4.0 Advanced Hybrid Closed -Loop (AHCL ) (PID + 
Fuzzy Logic) pump with the Guardian Sensor (3) continuous glucose 
monitoring sensor.  
Objectives  The objective of the study is to compare the efficacy and safety of AID system 
with PID (Minimed 670G 3.0 HCL ) to an AID system with combined PID + 
Fuzzy Logic algorithm (Minimed 670G 4.0 AHCL). In particular, the trial will 
test the hypothesis that the Minimed AHCL can reduce daytime 
hyperglycemia, currently the biggest challenge for AID systems, without 
increasing hypoglycemia.  
Study Design  Randomized  crossover trial with two 12 -week crossover periods  in auto mode  
preceded by a run -in phase . 
Number of Sites  Approximately seven sites  
Endpoint  Primary Efficacy Outcome:   
The co -primary outcomes are differences in CGM -measured metrics between 
periods:  
• Superiority for percent of time >180 mg/dL (10.0 mmol/L) from 6AM to 
11:59PM and  
• Non-inferiority for percent of time <54 mg/dL (3.0 mmol/L) during the 
entire 24 hour period.  
 
Key Secondary Efficacy Outcomes:  
• CGM derived indices over the first 84 days of each treatment period for 24 
hours ( excluding time before auto mode is turned on ), daytime (6AM -
11:59PM), nighttime (12AM -5:59AM), and for each post -meal period 
(meal starts at the time the carbohydrate is entered ), measured for up to 
three  hours a fter a meal (or until another carbohydrate is entered ): 
o Mean glucose  
o Coefficient of variation  
o Percentage of sensor glucose  readings in the range of  70 to 180 
mg/dL  (3.9 to 10.0 mmol/L)  and 70 to 140 mg/dL  (3.9 to 7.8 
mmol/L)  
o Percentage of sensor glucose  readings  >180  mg/dL  (daytime is a 
co-primary outcome) and >250 mg/dL  (10.0 and 13.9 mmol/L, 
respectively)  
o Peak glucose and change in glucose from the start of the meal to 
the peak (only calculated for post -meal periods)  
• Amount of total, basal , and bolus daily insulin over the first 84 days of 
each treatment period (excluding time before auto mode is turned on) for 
24 hours, daytime (6AM -11:59PM ), nighttime (12AM -5:59AM ), and for 
FLAIR  CLINICAL TRIAL PROTOCOL V7.[ADDRESS_1185091] -meal period (meal starts at the time the carbohydrate is entered ), 
measured for up to three  hours after a meal (or until another carbohydrate 
is entered ) 
• HbA1c  
• BMI  
 
Key Safety Outcomes  
• Percentage of sensor glucose readings <54 mg/dL (overall is a co -primary 
outcome) and <70 mg/dL (3.0 and 3.9 mmol/L, respectively)  
• DKA events  
• Severe hypoglycemia events  
 
Other Outcomes  
• Amount of total basal and bolus insulin at daytime, nighttime, and post -
meal analyzing both total units and units/kg  
• Human Factors and Diabetes Technology Attitude and Human Factors 
questionnaires  
Population  
 
 
 Major Eligibility Criteria  
• Type 1 diabetes (T1D) for at least one year, using an insulin pump or 
multiple daily injections of insulin  
• Age 14 -<30 years  
• HbA1c 7.0% -11.0% 
• For females, not currently known to be pregnant, be breast -feeding, or 
planning to become pregnant within the planned study duration.  
Major Exclusion Criteria  
• Concomitant disease that influences metabolic control or HbA1c 
interpretation  
• Use of antidiabetic agents other than insulin  
• One or more epi[INVESTIGATOR_116651] (hypoglycemia requiring 
treatment by [CONTACT_19015]) within the previous 6 months  
• One or more epi[INVESTIGATOR_852290] 6 
months prior to screening  
• Clinically significant nephropathy (eGFR <45 mL/min) or on dialysis  
Sample Size  Enrollment will proceed with the goal of at least 100 participants completing 
the crossover trial. A maximum of 135 individuals may be enrolled and a total 
of approximately 112 are expected to enter the crossover trial.  
Treatment Group  Random assignment ( 1:1) ratio to either begin with the PID ( 670G 3.0 HCL ) 
AID system or the PID + Fuzzy Logic (670G 4.0 AHCL) AID system and 
then crossover to the other respective treatment.  
Participant 
Duration  Approximately 28-36 weeks  
Protocol 
Overview/Synopsis  Screening and Enrollment  
• Informed consent will be signed and eligibility will be assessed  
• Medical history and physical examination  
• HbA1c measurement  
• Urine pregnancy test (if applicable)  
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 12 OF 74 
 PARTICIPANT 
AREA  DESCRIPTION  
• Human Factors and Diabetes Technology Attitude Surveys  
 
Run-In Period  (2-8 weeks)  
Pump Run -In (670G 3.0 HCL ) 
Eligible participants will use the study 670G 3.0 HCL  pump during the run-
in. Participants who were pump users at screening may skip the Pump Run -
In period (but must participate in the Pump+CGM Run -In period)  per 
investigator discretion. 670G auto mode users  may use the 670G pump in 
auto mode.  
 
Standardized pump training will be provided to study participants and their 
diabetes care partners (for participants <18 years old). The study team will 
assist the part icipant in study pump infusion site initiation and will start the 
participant on the study pump. For current pump users, the study pump will 
be programmed with the participant’s usual basal rates and pump 
parameters. The participant’s personal pump will be  removed. Participants 
may continue to use their personal CGM if applicable.  
 
The pump will be used for at least two weeks  during Pump Run -In, with the 
option of repeating Pump Run -In for an additional two weeks per 
investigator discretion. Contact [CONTACT_852313]. Prior to each contact, participants will be asked to 
upload device data for study staff to review.  
 
After completion of Pump Run -In, participants will proceed to use the study 
CGM along with the study 670G 3.0 HCL  pump during the Pump+CGM 
Run-In period.  
 
Pump+CGM Run -In (670G 3.0 HCL  + Guardian Sensor (3))  
All participants must complete a two -week run -in period with the use of the 
study pump and CGM before being randomized into the crossover trial. 
During Pump+CGM Run -In, the predictive low glucose suspend feature will 
be turned on and auto mode will be off (i.e. manual mode). Participants who 
were 670G auto mode users at screening may use the pump in auto mode.  
 
Standardized device training will be provided to study participants and their 
diabetes care partners (for participants <18 years old). Personal pumps and 
CGMs will be removed during the Pump+CGM Run -In period as applicable.  
 
Contact [CONTACT_852314]. Prior to 
each contact, participants will be asked to upload device data for study staff to 
review.  
 
Run-In Assessment  
Successful completion  of Pump Run -In is per investigator discretion.  Pump 
Run-In may be repeated once.  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 13 OF 74 
 PARTICIPANT 
AREA  DESCRIPTION  
Successful completion of the Pump+CGM Run-In requires CGM data to be 
collected on at least 8 0% of the possible time in the prior [ADDRESS_1185092] three blood glucose meter ( BGM ) tests per day will also be 
required. If these are not achieved, the Pump+CGM Run-In period may be 
repeated once . 
 
Randomization into the Crossover Tr ial 
Eligible participants who successfully complete the Pump+CGM Run -In will 
be randomly assigned to begin with one  Automated Insulin Delivery  (AID) 
system during P eriod 1 and then crossover to the other AID system during 
Period 2. The two study AID system s (treatments) are: 
• 670G 3.0 Hybrid Closed -Loop (HCL) (PID)  insulin pump + Guardian 
Sensor (3) CGM  
• 670G 4.0 Advanced  Hybrid Closed -Loop ( AHCL) (PID + Fuzzy Logic)  
insulin pump  + Guardian Sensor (3) CGM  
 
Home Use of AID System during the Crossover Trial  
Period 1  (~13 weeks)  
Participants and their diabetes care partners (for participants <18 years old) 
will be trained by [CONTACT_852315], meal bolusing, and 
exercise.  
 
Training will also be provided in performing specific tasks including the 
following:  
• Confirming pump parameters  
• When not to use or rely on auto mode particularly during significant 
illness or acetaminophen use  
• CGM calibration instr uctions  
• Meal bolus procedures  
• What to do when exercising while using the system  
• How to react to safety/alert notifications  
• How to perform fingerstick blood glucose measurements in accordance 
with the labeling of the study CGM device  
• When and how to contact  [CONTACT_852316] -up appointments. Participants will be asked 
to upload data before each contact [INVESTIGATOR_618482] e very two weeks.  
 
After auto mode training has been completed, participants will proceed with 
home use of the AID system (meaning free -living use at work, home, etc.) 
during Period 1 with either the 670G 3.0 HCL  or 670G 4.0 AHCL pump. The 
predictive low glu cose suspend feature will be on.  
 
The system will initially be used with auto mode deactivated (except for 670G 
auto mode users at screening who may activate auto mode  if using the 670G 
3.0 HCL pump ) until participants are contact[INVESTIGATOR_530] 6 -10 days into Period 1  with 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 14 OF 74 
 PARTICIPANT 
AREA  DESCRIPTION  
instructions to activate auto mode. Participants will then conti nue using the 
AID system for 12 weeks after auto mode is initialized.  
 
Participants will be expected to use auto mode at all times at home with some 
exceptions (e.g. times of illness, ac etaminophen use).  
 
HbA1c, C -peptide, and glucose levels will be collected for central lab analysis 
at the beginning of Study Period 1. Human Factors and Diabetes Technology 
Attitude Surveys will be administered at the end of Study Period 1.  
 
Period 2  (~13 weeks)  
At the beginning of Period 2, a urine pregnancy test will be completed as 
applicable. Eligible participants will then use the other AID system during 
Period 2. The procedures in Period 1 will be repeated in Period 2. At the end 
of the 12 -weeks  of AID use  in auto mode  at home, the participant will 
complete a final study visit which may be conducted at home or remotely , if 
an in -clinic visit is not possible.  
 206 
  207 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 15 OF 74 
 Schematic of Study D esign  208 
 209 
Figure 1. Schematic of Study Desi gn 210 
  211 
 212 
 213 
 214 
  215 

FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 16 OF 74 
 Schedule of Study Visits and Procedures  216 
 217 
Table 1. Schedule of Visits and Procedures during Screening and Run -In 218 
 Screening /Start of 
Run-In5 Pump Run -In1 Pump+CGM Run -In1 
1 week after 
screening  (±2d)  2 weeks after 
screening  (+3d)  1 week after screening 
or end of pump run -in  
(±2d) 2 weeks after screening 
or end of pump run-in 
(+3d) 
Visit (V) or Contact (C)  V C V C V (Same as Rand Visit) 
Informed Consent   X     
Inclusion/Exclusion  X     
Medical history/physical exam  X     
Height, weight, blood pressure  X     
HbA1c – point -of-care or local lab  X     
Study pump training  X2     
Study CGM training X3  X   
Questionnaires - Diabetes Tech 
Attitude + Human Factors  X     
AE Assessment   X X X X 
Upload device data from home   X  X  
Upload device data at clinic visit    X  X 
Review blood sugars and make 
insulin adjustments as needed   X X X X 
Pregnancy t est4 X     
1Run-in periods may be repeated once . 
2Pump training will occur after participant is determined to be eligible.  
3Current pump users at screening may skip Pump Run-In and proceed directly to Pump+CGM Run-In at investigator’s discretion . CGM training will occur 
after participant is determined to be eligible.  
4Additional pregnancy tests to be performed any time pregnancy is suspected.  
5The Screening and start of run -in training visits may occur on the same day or separate days  but no more than 14 days apart . 
 219 
 220 
  221 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 17 OF 74 
  222 
Table 2. Schedule of Visits and Procedures During the Crossover Trial  223 
 Randomization  Crossover Period 1 (P1)  Crossover Period 2 (P2) 
Auto 
Mode 
Initiation Time from Auto Mode Initiation Auto 
Mode 
Initiation Time from Auto Mode Initiation 
-6-10d1 0d1,4 244 
hours  5d4 ± 
2d  2w 
± 
4d 4w 
± 
4d 6w 
± 
4d 9w 
± 
4d 12w + 7d  
(and -6-
10d from 
P21) 0d1,4 244 
hours  5d4 ± 
2d  2w 
± 
4d 4w 
± 
4d 6w 
± 
4d 9w 
± 
4d 12w 
+ 7d 
Visit (V) or Contact (C)  V C C C V C V C V C C C V C V C V/C 
Re-review of eligibility  X                 
Assessment visit  X    X  X  X    X  X  X 
Height, weight, blood 
pressure  X        X        X 
Central lab – HbA1c  X        X        X 
Central lab – random 
C-peptide and glucose  X                 
Auto mode training  X                 
Turn auto mode on   X        X        
Setpoint evaluation2     X X X X     X X X X  
Questionnaires - 
Diabetes Tech Attitude 
+ Human Factors          X        X 
AE Assessment  X X X X X X X X X X X X X X X X X 
Upload device data 
from home   X X X  X  X  X X X  X  X  
Upload device data at 
clinic visit  X    X  X  X    X  X  X 
Review glucose patterns  X X X X X X X X X X X X X X X X X 
Pregnancy test3 X                 
1Auto mode initiation will begin [ADDRESS_1185093] be completed by [CONTACT_648].  
224 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 18 OF 74 
 
 Background Information  225 
 226 
 Introduction  227 
Type I diabetes (T1D) causes autoimmune pancreatic beta cell destruction and lifelong [ADDRESS_1185094] 234 
decade, the use of insulin pumps and sensors and their combination (sensor -augmented pumps) [ADDRESS_1185095] shown advances towards improving glucose control.2-4 However, recent data from diabetes 236 
centers in Europe and the [LOCATION_002]  (US) indicate that the glycemic control achieved is still 237 
not satisfactory and is complicated by [CONTACT_606944],5, 6 despi[INVESTIGATOR_852291] 238 
advanced technological tools now available.7 Some progress is being made with the introduction 239 
of the thr eshold suspend or low glucose suspend (LGS) sensor and pump systems in the United 240 
States. We now need to combine predictive features with LGS features to minimize 241 
hyperglycemia as well,8 without causing anxiety and burden for patients and caregivers due to  242 
the demand for continual attention to how well the systems cover meals, snacks and periods of 243 
illness. This is especially true in adolescents and some young adults whose compliance with 244 
treatment can be low, with 50% omitting or delaying insulin boluses n eeded for meals.9 245 
Automated decision support systems, and ultimately, full automated management solutions, are 246 
strongly desired by [CONTACT_23270] T1D and their caregivers to improve metabolic control and 247 
relieve them of the stress and burden of daily treatm ent of this chronic disease.  248 
 249 
 Background: Studies descriptions below include data from PID, MD -Logic, and the 250 
combined algorithms:  [ADDRESS_1185096] been the proportional -integral -derivative (PID) and model 254 
predictive controller (MPC).10-[ADDRESS_1185097] approach to algorithms uses fuzzy logic 256 
algorithms (such as the MD -Logic) to modulate insulin delivery based on a set of rules that 257 
imitates the line of reasoning of diabetes practitioners, which in turn are b ased on common 258 
medical knowledge and the experience of traditional treatment.14 The MD -Logic controller 259 
applies a basal -bolus approach of insulin delivery with event -driven treatment (i.e., meals and 260 
exercise) and a personalized system setting, learning ca pacity, and safety alerts and embedded [ADDRESS_1185098] 8 years, the MD -Logic system has been tested in several 264 
clinical studies: in research centers, diabetes camps, and at patients’ homes in Israel and Europe. [ADDRESS_1185099] importantly, was foun d to 266 
be safe in daily routine use.16 Since then, the system has been evaluated in several home studies, 267 
in free -living conditions, and for longer durations: [ADDRESS_1185100] of the system at home for day and night use : The first feasibility clinical 288 
studies  using MD -Logic were conducted in 2009 in 7 adults with T1D, aged 19 to 30 years. All 289 
study participants underwent 14 full, closed -loop control sessions of 8 hours (fasting and meal 290 
challenge conditions) and 24 hours  of full closed -loop control with three meals. During the 24 - 291 
hour control, 73% of the sensor values ranged from 70 to 180 mg/dL (3.9 -10.0 mmol/L), 27% 292 
were >180 mg/dL(10.0 mmol/L), and none were <70 mg/dL (3.9 mmol/L). There were no events 293 
of symptomatic h ypoglycemia during any of the trials. During the overnight period, 91% of the 294 
time glucose concentrations were within 70 -140mg/dL (3.9 -7.8 mmol/L), and mean glucose was 295 
112 ± 5 mg/dL (6.2 ± 0.3 mmol/L) with no epi[INVESTIGATOR_852292] 63 mg/dL (3.5 296 
mmol/L).20  297 
 298 
Next, the system was tested with and without evening exercise in three adolescents and four 299 
adults who underwent two sessions with the MD -Logic: one started at dinner alone and the other 300 
one at dinner time following exercise. These sessions were compared with data derived from 301 
nights spent at home with SAP in a similar scenario to this proposed study protocol. The mean 302 
percentage of time spent in the target range of 63 -140 mg/dL (3.5 -7.8 mmol/ L) was 85% (78% to 303 
92%) for the MD -Logic sessions compared with 27% (6% to 57%) using SAP, respectively 304 
[median (interquartile range -IQR)]. During the overnight closed -loop sessions at dinner alone, 305 
92±9% of the sensor values ranged within target, compare d with 73±19% for the sessions 306 
following exercise ( P=0.03). No hypoglycemic events occurred during the closed -loop sessions. 307 
This study demonstrated the ability of the system to cope with evening exercise and to "support" 308 
meal insulin delivery (i.e., the s ystem gave correction boluses or lowered basal insulin as needed 309 
to cope with the meal).21 310 
 311 
Next was a multicenter, multinational study conducted in Slovenia, Israel, and [LOCATION_013] in 312 
an inpatient setting in 12 children, adolescents, and young adults randomly assigned to 313 
participate in two sequential overnight sessions: one using insulin pump treatment and the other 314 
MD-Logic closed -loop insulin delivery. Results showed that three events of nocturnal 315 
hypoglycem ia occurred during control nights and none during MD -Logic nights ( P=0.18).The 316 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 20 OF 74 
 percentage of time spent in the target range of 63 -140 mg/dL (3.5 -7.8 mmol/L) was significantly 317 
higher during MD -Logic nights 76% (54% to 85%) compared with 29% (11% to 44%) dur ing 318 
insulin pump nights, P=0.02 [median (IQR)].The mean glucose level overnight was reduced by 319 
36 mg/dL (2 mmol/L) with the use of MD -Logic ( P=0.02), with significantly less glucose 320 
variability than that of the pump therapy ( P<0.001).22  321 
 322 
The subsequent study transitioned use of the device to the outpatient setting in a 323 
multicenter, multinational, randomized, crossover trial in which the short -term safety and 324 
efficacy of the MD -Logic System was assessed for nocturnal glucose control in 56 children and 325 
adolescents with T1D at a diabetes camp who participated in two consecutive overnight sessions, 326 
one night with MD -Logic and the second night with SAP therapy, with the order of nights 327 
randomly assigned. The prim ary endpoints were overnight hypoglycemia (measured two ways, 328 
number of sensor readings below 63 mg/dL (3.5 mmol/L) and a more complex measure of 329 
epi[INVESTIGATOR_852293] 60 mg/dL(3.3 mmol/L) and 330 
mean overnight gluco se concentrations. On MD -Logic system nights, compared with SAP 331 
nights, there were significantly fewer epi[INVESTIGATOR_852294] 63 mg /dL(3.5 332 
mmo/l) (7 vs. 22) and significantly shorter periods or epi[INVESTIGATOR_852295] 333 
60 mg/dL (3.3 mmol/L) ( P=0.003 and  P=0.02, respectively). Median values for individual mean 334 
overnight glucose concentrations were 126.4 mg/dL (7.0 mmol/L) (IQR - 115.7 to 139.1 mg/dL) 335 
with MD -Logic and 140.4 mg/dL (7.8 mmol/L) (IQR - 105.7 to 167.4 mg/dL (5.9 t o 9.3 336 
mmol/L)) with SAP therapy. No serious adverse events were reported. This study demonstrated 337 
the safety and efficacy of short -term use of MD -Logic outside the hospi[INVESTIGATOR_307], during diabetes 338 
camp, with physical activities, and buffet -served meals. MD -Logic system therapy was found to 339 
be superior to SAP therapy, with a reduced risk of nocturnal hypoglycemia with tighter glucose 340 
control.23  341 
 342 
Studies next focused on home use of the MD -Logic device for a 4 -nigh t duration using a 343 
single -blind, randomized, multicenter, multinational, crossover study designed to validate the 344 
feasibility, safety, and efficacy of MD -Logic in T1D at patients’ homes.16 Seventy -five 345 
participants (aged 10 to 54 years; average HbA1c 7.8±0.7%) were randomly assigned to 346 
participate in two overnight crossover periods, each including four consecutive nights: one under 347 
MD-Logic system and the second under SAP therapy at patients’ homes in real -life conditions. 348 
Investigators were masked to treatment intervention. Primary endpoints were the time spent with 349 
glucose concentrations below 70 mg/dL (3.9 mmol/L), and the percentage of nights in which the 350 
mean overnight glucose concentrations were within 90-140 mg/dL (5.0 - 7.8mmol/L). The study 351 
results showed that on nights in which MD -Logic was used, time spent in hypoglycemia was 352 
significantly reduced ( P=0.004) compared with nights in which SAP therapy was used. The 353 
percentage of individual nights in wh ich mean overnight glucose concentration was within 90 – 354 
140 mg/dL (5.0 – 7.8 mmol/L) was decreased for SAP, with a median (and IQR) of 75 mg/dL 355 
(4.2 mmo/l) (42, 75), and 50 mg/dL (2.8 mmol/L) (25, 75) for MD -Logic and SAP nights, 356 
respectively; P=0.008. 16 Exploratory comparisons of the intention -to-treat cohort demonstrate 357 
the safety and efficacy of MD -Logic in terms of significantly reducing the risk of nocturnal 358 
hypoglycemia parameters while improving ove rnight glycemic control and reducing the risk of 359 
nocturnal hyperglycemia. The same amount of total insulin doses were used during closed -loop 360 
and control nights. No serious adverse events were reported. Mean overnight glucose 361 
concentrations were more consi stent and converging to a narrow range during closed -loop nights 362 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 21 OF 74 
 compared with open -loop nights. In addition, worries about epi[INVESTIGATOR_852296] 363 
significantly reduced using the fear -of-hypoglycemia questionnaire when using the MD -Logic 364 
System comp ared with SAP therapy ( P=0.017). Perceived ease of use significantly increased 365 
(P=0.002), and the overall satisfaction mean score after the intervention was 3.02±0.54 (range 0 - 366 
4), demonstrating a high level of satisfaction with the system.24  367 
 368 
The device was next tested in a randomized crossover study designed to evaluate the safety 369 
and efficacy of MD -Logic system for overnight use in T1D at patients’ homes for 6 weeks.25 370 
Twenty -four participants (aged 12 to 43 years; average HbA1c 7.5±0.8%) were randomly 371 
assigned to participate in two overnight crossover periods, each six weeks of conse cutive nights: 372 
one under MD -Logic and the second under SAP therapy. MD -Logic significantly reduced time 373 
spent in hypoglycemia at night ( P=0.02) and increased the percentage of time spent in the target 374 
range of 70 -140 mg/dL (3.9 – 7.8 mmol/L) ( P=0.003) compared with SAP. The time spent in 375 
substantial hyperglycemia (>240 mg/dL) was reduced by a median of 52.2% (IQR, 4.8 -72.9%) 376 
(P=0.001) under MD -Logic compared with SAP therapy. Total insulin doses were lower in the 377 
MD-Logic group than in the SAP n ight group ( P=0.04). The average daytime glucose 378 
concentration after closed -loop operation were reduced by a median of 10.0 mg/dL (0.5 mmol/L) 379 
(IQR -2.7, 19.2, P=0.017) while lower total insulin doses were used ( P=0.038). One severe 380 
hypoglycemia event was observed during a SAP night and none using MD -Logic. 25 381 
 382 
The MD -Logic HCL  system was then tested over a weekend at home for 60 hours and glucose 383 
control was compared to that achieved on SAP therapy. The pri mary endpoint was the time 384 
within 70 -180 mg/dL (3.9 -10.0 mmol/L). Twenty -two patients were evaluated. Preliminary 385 
unpublished data from the intention -to-treat analysis showed that the time within the desired 386 
range was increased by a median of 19% during MD -Logic HCL control compared with SAP. 387 
The time spent in hypoglycemia and the amount of insulin use was the same during MD -Logic 388 
HCL as with SAP. Time spent in hyperglycemia above 180 mg/dL (10.0 mmol/L) was reduced 389 
by 32% during the MD -Logic HCL control co mpared with SAP.  390 
 391 
The conclusion from this series of studies is that the MD -Logic (fuzzy logic algorithm) system 392 
was safe and effective in both inpatient and outpatient settings.  393 
 394 
Next the studies using the Medtronic HCL  (PID algorithm) system are outline d.  395 
 396 
 Medtronic HCL Studies  397 
The feasibility of the Medtronic HCL algorithm has been proven in pediatric, adolescent, and 398 
young adult patients.26-32 In a study of eight participants age 14 -40 using the Medtronic HCL 399 
system with PID control algorithms on an android device compared to SAP with LGS, there was 400 
no significant difference in total time spent in target but hypoglycemia (< 2.8 mmol/L) was all 401 
but eliminated with HCL (1 vs. 9, p=.04) and no adverse effects were reported.29 In response to 402 
promising data from these studies, Medtronic incorporated a more adaptive algorithm directly 403 
into the pump  hardware (MiniMed 670G) and this Medtronic HCL platform has just been tested 404 
in 124 individuals (adolescents and adults at 9 centers in the US and one center in Israel) in a 3 405 
month pi[INVESTIGATOR_852297] 2016 and was published in J AMA, 406 
September 15, 2016.  Of the 124 participants (mean age, 37.8years [SD, 16.5]; men, 44.4%), 407 
mean diabetes duration was 21.7 years, mean total daily insulin dose was 47.5U/d (SD, 22.7), 408 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 22 OF 74 
 and mean HbA1c was 7.4% (SD, 0.9).  Over 12 389 patient -days, no epis odes of severe 409 
hypoglycemia or ketoacidosis were observed. There were 28 device related adverse events all 410 
resolved at home (including skin irritation, infusion set malfunction, batteries needing 411 
replacement and damage to the pump screen).  There were 4 SAE ’s but none related to the 412 
system. The system was in closed -loop 87.2% of the time and the MARD of the Guardian Sensor 413 
(3) was 10.3% (SD 9.0).  Efficacy data showed is shown in the table  below  from Table 2 in the 414 
JAMA publication shown below:  415 
 416 
 417 
 418 

 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 23 OF 74 
 The 670G h ybrid closed loop system was approved by [CONTACT_852317] 28, 2016 and has 419 
been marketed for clinical use since the Spring of 2017 in the [LOCATION_002].  Eighty percent of 420 
the 670G pi[INVESTIGATOR_852298] d in an extension study that has been si nce 421 
completed.  422 
 423 
Several of the PIs for this study are PIs on this Medtronic pi[INVESTIGATOR_852299] 424 
familiar with the system safety and effectiveness, particularly the ability to control blood glucose 425 
overnight and between meals. However, as with ot her HCL systems being evaluated, there is still 426 
potential for improvement in mealtime glycemic control by [CONTACT_852318] 427 
bolus insulin delivery component of the fuzzy logic algorithm as described in this proposal (such 428 
as the PID + Fuzzy Logic / Advanced Hybrid Closed -Loop (AHCL)  / 670G 4.0  System).  The 429 
room for further glucose control  can be appreciated from the 670G pi[INVESTIGATOR_852300] 430 
figure below (2) . [ADDRESS_1185101] that in the 670G pi[INVESTIGATOR_852301] 435 
that the percent of time with sensor glucose reading >180 mg/dL (10.0 mmol/L) was higher in 436 
adolescents than adults and was higher in day time than the night time , therefore confirm ing 437 
particular room for improvement in time spent >1 80 mg/dL ( 10.0 mmol/L) in adolescents 438 
during the day  while using the 670G system, particularly in adolescents .  439 
 440 

 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 24 OF 74 
  441 
 442 
 443 
 444 
 Integrated Advanced HCL System In -Silico Testing  445 
The Advanced HCL  System has been evaluated with an in -silico (virtual) model and compared 446 
to the Medtronic HCL under carbohydrate (CARB) estimations that deviated from the actual 447 
CARB values by [CONTACT_717941] 50%. Medtronic created the in -silico model of T1D pump users [ADDRESS_1185102] the effectiveness of insulin dosing algorithms prior to clinical study. A total of 218 virtual 449 
patients (112 female, median total daily insulin dose =40 units, age 43 -55) were created using 450 
data from Medtronic’s large pool of SAP uploads in Carelink. T he model contains mathematical 451 
predictions of sensor glucose measurements validated using 51 days of Carelink uploads 452 
comparing model predictions to sensor glucose measurements of time >180 mg/dL (10.0 453 

 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 25 OF 74 
 mmol/L) and < 70 mg/dL (3.9 mmol/L). The model had bee n used successfully in the 454 
development of Medtronic’s HCL system.  455 
 456 
Table 3. Comparing HCL and Advanced AID System with a constant CARB estimation error  (a 457 
50% underestimation) below summarizes the simulation results of the Advanced HCL system 458 
when CARB estimation was constantly underestimated by 50%. The simulation results indicate 459 
that, there is a significant  improvement to the efficacy of glycemic con trol in the Advanced HCL  460 
system by [CONTACT_852319] -Logic algorithms, especially in the presence of CARB 461 
estimation inaccuracies.  462 
 463 
Table 3. Comparing HCL and Advanced AID System with a constant CARB estimation 464 
error  (a 50% underestimation)  465 
Parameter  HCL  
Mean ± SD (Median)  Adv HCL  
Mean ± SD (Median)  
% Time > 250 mg/dL  15 ± 9 (14)  12 ± 8 (12)  
% Time > 180 mg/dL  37 ± 11 (37)  33 ± 9 (33)  
% Time < 70 mg/dL  0 ± 0 (0)  0 ± 1 (0)  
% Time 70 – 180 mg/dL  63 ± 11 (63)  67 ± 9 (67)  
Mean Senor Glucose  177 ± 19 (175)  169 ± 14 (168)  
AUC < 70 mg/dL  0 ± 0 (0)  0 ± 0 (0)  
AUC > 180 mg/dL  27 ± 15 (25)  22 ± 12 (20)  
 466 
 Further Studies and Updates to the Advanced HCL System:  467 
Clinical testing to ensure safety of the integrated Advanced HCL (PID and fuzzy logic 468 
algorithms combined) was conducted in Israel as part of NIDDK bridge grant funding in 469 
anticipation of this proposal (NIDDK/UC4DK108611, Home Use of MD -Logic Automated 470 
Insulin Deliv ery System: Safety and Efficacy , PIs Bergenstal and Phillip) to compare the [ADDRESS_1185103] of 20 -60 472 
participants with T1D in a camp setting for 3 -5 days.  This study was completed successfu lly 473 
showing that the PID and fuzzy logic algorithms could be combined safely and effectively in this 474 
small pi[INVESTIGATOR_799].  475 
 476 
Following the successful combination of the PID and fuzzy logic algorithms, Medtronic made a 477 
few additional adjustments to some software settings for the MiniMed 670G 4.0 AHCL system 478 
which FLAIR study will be comparing to the 670G 3.0 (commercial) system. These additional 479 
features that will be present in the 670G 4.0 AHCL system are compared to the current 670 3.0 480 
system in Table 4 below .  Note in Auto mode the 670G 4.0 AHCL system fine tunes some of the 481 
features to allow patients to spend more time in auto mode. In addition the glucose target 482 
setpoint can be set at 100 mg/dL  (5.6 mmol/L)  or 120 mg/dL  (6.7 mmol/L)  (the latter of which is 483 
like the 67 0G 3.0  HCL ). The FLAIR protocol will start with a set point of 120 mg/dL  (6.7 484 
mmol/L)  for all participants and move to 1 00 mg/dL (5.6 mmol/L)  as long as there is no  data 485 
indicating an undue risk of hypoglycemia after review of  glucose/insulin data reports.  An 486 
additional optional feature of auto correction boluses is present in the 670G 4.0 AHCL system (a 487 
function of the fuzzy logic algorithm component).  Table [ADDRESS_1185104] been tested in an inpatient and outpatient 494 
setting (in Aust ralia) then fine -tuned and tested again in an inpatient (stress testing: meals, 495 
exercise and testing glucose excursions) and outpatient setting in Israel. After final adjustments 496 
and reviewing the safety and efficacy parameters the configuration of the 670 G 4.0 AHCL was 497 
determined to be ready for comparing to the 670G 3.0  HCL  version in FLAIR.  498 
 499 
 500 
Table 4. 670G 3.0 HCL vs 670G 4.0 AHCL  501 
 MiniMed 670G 3.0 (MMT -1780, MMT -1781, 
MMT -1782)  MiniMed 670G 4.0 (MMT -1741, MMT -1742)  Manual Mode  
Continuous delivery of basal insulin and delivery of user activated insulin boluses.  
When used with Continuous glucose monitoring (CGM), the sensor signals are converted by [CONTACT_852320] (based on calibration values from a blood glucose meter) which are transmitted 
to the pump for display to the user.  
MiniMed 670G 3.0  (MMT -1780, MMT -1781, 
and MMT -1782) allows the user to enable one of 
the following features to suspend delivery of 
insulin as follo ws:  
 
“Suspend on Low”  will suspend when sensor 
glucose falls below the predefined threshold value  
 
“Suspend Before Low”  will suspend delivery of 
insulin when the sensor glucose is predicted to the 
fall below predefined threshold values.  The MiniMed 670G 4.0 (MMT -1741, MMT -1741) allows the 
user to enable the following feature to suspend delivery of 
insulin as follows:  
 
“Suspend on Low”  will suspend when sensor glucose falls 
below the predefined threshold value  
 
 
“Suspend Before Low”  will suspend delivery of insulin when 
the sensor glucose is predicted to the fall below predefined 
threshold values.  
 
Auto Mode  
Automatically adjusts basal insulin using the control algorithm of PID -IFB (Proportional integral derivative 
controller with insulin feedback) to regulate the user’s sensor glucose levels  
Temporary target (user settable) remains unchanged with a setpoint  of 150 mg/dL.  
Target Setpoint of 120 mg/dL  (6.7 mmol/L)  Target Setpoint of 100 mg/dL or 120 mg/dL  (5.6 mmol/L or 
6.7 mmol/L, respectively)  
Correction bolus target is 150mg/dL (8.3 
mmol/L)  Correction bolus target is 120 mg/dL (6.7 mmol/L)  
Safeguards in Auto Mode include the following:  
 
• Min insulin delivery timeout 2.5 hours  
 Safeguards in Auto Mode are being fine -tuned to allow more 
time in Auto mode.  
 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 27 OF 74 
 • Max insulin delivery timeout 4 hours  
• Sensor integrity check logic to allow into 
Auto Mode  
 
• Safe basal will not exceed 90 min  
• Model Supervisor detects under read (30 
min)  
• Missed Transmission switches to safe basal 
if there is a missed transmission  
• Low Glucose Alert will be a mandatory alert 
when the user is 50 mg/dL.  
• High Glucose Alert will alert and kick user 
out of Auto Mode when they are   > 250 
mg/dL for 3 hours and  alert when the user is 
> 300 mg/dL for 1 hour.  • Min insulin delivery timeout 3-6 hours  (dependent on the 
insulin on board)  
• Max insulin delivery timeout 7 hours   
• Sensor integri ty check modified to use sensor calibration 
logic to allow into Auto mode  
 
 
 
 
• Safe basal will not exceed 4 hours   
• Model Supervisor detects under -read (2 hrs.)  
• Missed Transmission switch to safe basal if there is a 
missed transmission  
• Low Glucose Alert will be a mandatory alert when the 
user is 50 mg/dL.  
• High Glucose Alert will alert but not kick the user out 
of Auto Mode when they are > 250 mg/dL for 3 hours. 
The alert for > 300 mg/dL for 1 hour is being removed.  
N/A Auto Correction Bolus  is an optional feature (user enabled) to 
deliver correction boluses automatically without any user input 
or acknowledgement.  
N/A Safe Meal Bolus  has the ability to further reduce the amount of 
a meal bolus if it is predicted to increase the risk of post -
prandial hypoglycemia  
N/A Non-Adjunctive capabilities  permits correction boluses to use 
sensor glucose values if a meter BG is not available. All other 
correction bolus calculations, including the application of the 
Safe Correction Bolus logic, remain t he same.  
 [ADDRESS_1185105] gap between desirable outcomes and 510 
those achieved, as shown in data from the T1D Exchange ( Figure 2. T1D Exchange data 511 
showing relationship between age and glycemic control  below).[ADDRESS_1185106] of two AP approaches (PID and MD -Logic/fuzzy logic algorithms) in 522 
an integrated Advanced HCL  System (670G 4.0 AHCL) in order to provide important data on 523 
the safety and efficacy of this promising AP system. If outcomes are positive, it will help 524 
promote the recognition of such systems as  an effective and safe T1D management solution that 525 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 28 OF 74 
 may address some of the gaps in glucose control (e.g., meals, snacks, illness) not adequately [ADDRESS_1185107] generalization.  531 
 532 
 533 
Figure 2. T1D Exchange data showing relationship between age and glycemic control  534 
 535 
 536 
 Automated Insulin Delivery System Description  537 
The FLAIR study will compare two hybrid closed loop systems, the Minimed 670G 3.0 HCL 538 
(PID) and the Minimed 670G 4.0 Advanced Hybrid Closed -Loop AHCL (PID + Fuzzy Logic) 539 
pump. The sensor and infusion set will be the same in both systems. A schematic of the sys tem 540 
hardware components of the closed loop system is depi[INVESTIGATOR_6517] 3. Schematic of system 541 
hardware components  below.  542 

 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 29 OF 74 
 Figure 3. Schematic of system hardware components  543 
 544 
 545 
 Potential Risks and Benefits of the Investigational Device  546 
Study System  547 
Even though the study system has been tested prior to this study, there is still a risk that parts of the 548 
system may not function properly.  The following are possible  reasons the system may deliver too 549 
much insulin or incorrectly stop insulin delivery : 550 
• CGM sensor reads higher or lower than the actual glucose level which increases risk for 551 
hypoglycemia and hyperglycemia with automated insulin delivery system ; 552 
• Acetaminophen interference causing the CGM sensor to read high than actual glucose 553 
levels;  554 
• Device malfunctions that could produce a suspension of insulin delivery or over delivery of 555 
insulin.  556 
 557 
Potential risks associated with insulin pump therapy include:  558 
• Slight discomfort at the time of insertion of the insulin delivery cannula (common)  559 
• Slight bruising at the site of insertion (common)  560 
• Infusion set and cannula occlusions (common) resulting in hyperglycemia or D KA 561 
• Insulin pump malfunction and mechanical problems (common)  562 
• Lipodystrophy/lypoatrophy (common)  563 
• Bleeding at insertion site (rare)  564 
• Infection at the site of insertion (rare)  565 
• Allergy to the insulin delivery cannula or adhesive (rare)  566 
• Allergy to insulin (very rare)  567 
 568 
Continuous Glucose Monitoring  569 

 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 30 OF 74 
 Potential risks associated with CGM:  570 
• Slight discomfort at the time of insertion of CGM (common)  571 
• Slight bruising at the site of insertion (unlikely)  572 
• Bleeding at insertion site (common)  573 
• Infection at the site of insertion (rare)  574 
• Allergic reaction to the CGM sensor adhesive material (common ) 575 
 576 
If a skin reaction is classified as severe (the observation is noticeable and bothersome to 577 
participant and may indicate infection or risk of infection or potentially life -threatening allergic 578 
reaction), an adverse event form will be completed.  579 
 580 
Risks  with Infusion Sets  Prevention and Mitigation  
Risks with infusion sets may include:  
• Localized infection  
• Skin irritation/redness  
• Bruising  
• Discomfort/pain  
• Bleeding  
• Irritation  
• Rash  
• Hyperglycemia secondary to infusion set 
occlusion or infusion site failure  
• Hyperglycemia secondary to site falling 
off 
• Anxiety associated with insertion  Prevention and mitigation include:  
• Follow the provided user guides 
for insertions and care of infusion 
sets. 
• If an infusion site becomes 
irritated or inflamed, the infusion 
set should be removed and another 
placed in a new location.  
• In case of hyperglycemia 
secondary to infusion set 
occlusion, remove current infusion 
set and replace with new infus ion 
set and give correction insulin if 
directed with syringe.  
• Follow the provided user guides 
for insulin pump management.   
• Training prior to study on device 
use and diabetes management 
principles and told to call with 
problems.  
Risks  with Insulin Admin istration and Pumps  Prevention and Mitigation  
Risks with the use of an insulin infusion pump 
may include the risk of malfunction of the 
components of the system (pump, software, 
infusion set and reservoir) as well as the risk of 
use error during use of the system. Device 
deficiencies or use errors can result in 
administration of too much or too little insulin 
which can lead to the following clinical 
consequences:  
 
• Hypoglycemia  
• Hyperglycemia  
• Diabetic ketoacidosis (DKA)  Prevention and mitigation include:  
• Follow the provided user guides 
for insulin pump management.   
• Training prior to study on device 
use and diabetes managem ent 
principles and told to call with 
problems.  
• Check SMBG 4 -6 times a day and 
also before driving (as applicable)  
or monitor the CGM .  
• Instructed to have glucose on hand 
for hypoglycemia  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 31 OF 74 
 • Severe hypoglycemia with or without 
associated seizure, coma or death  
• Kinked cannula leading to hyperglycemia  
• Infusion set disconnection from pump 
leading to hyperglycemia  
• Dislodged cannula leading to 
hyperglycemia  
• A pump error may lead to under delivery 
or over -delivery of insulin  
• Battery  failure – no insulin delivered 
leading to hyperglycemia  
• Insulin deterioration leading to 
hyperglycemia  
• Incomplete priming; fails to prime tubing 
and/or cannula, leading to hyperglycemia  
• Remove a reservoir, without suspending 
and reconnecting after a while  resulting in 
hyperglycemia  
• Patient not filling pump reservoir when 
needed leading to hyperglycemia  
• Magnetic Resonance Imaging resulting in 
pump/Guardian Link 3 Transmitter 
malfunction  
• Inaccurate insulin delivery due to sudden 
altitude changes.  
• Hypoglycemia or hyperglycemia from 
manual bolus  
• Hypoglycemia or hyperglycemia from 
computer hacking  • Change infusion set if suspected 
catheter occlusion or administer 
insulin with syringe for persistent 
hyperglycemia especially if 
ketones develop.   
• Parent(s)/guardian(s) of 
participants <18 years old) will be 
present at night with participants 
and will be trained on study device 
and diabetes management 
principles.  
 
Risks with hyperglycemia may include  
• DKA  
• Symptomatic ketosis  
• Cardiovascular event  
• Dehydration  
• Potassium and sodium imbalance  
• Shock  
• Altered mental status  
• Coma  
• Acidosis  Prevention and mitigation include:  
• Follow the provided user guides 
for insulin pump management.   
• Parent(s)/guardian(s)for 
participants <18 years old will be 
present at night with participants 
and will be trained on study device 
and diabetes management 
principles and told to call with 
problems.  
• Training prior to study on device 
use and diabetes management 
principles.  
• Check SMBG 4 -6 times a day  or 
monitor the CGM .  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 32 OF 74 
 • Alternative method of managing 
glucose levels should be available 
(insulin and syringe for example)  
Risks with  hypoglycemia may include:  
• Seizure  
• Coma  
• Altered mental status  
• Loss of consciousness  
• Cardiovascular event  
• Death  
• Risk of rebound hyperglycemia with 
ketosis  Prevention and mitigation include:  
• Follow the provided user guides 
for insulin pump management.   
• Parent(s)/guardian(s)  of 
participants < 18 years old will be 
present at night with participants 
and will be trained on study device 
and diabetes management 
principles and told to call with 
problems.  
• Training prior to study on device 
use and diabetes management 
principles.  
• Check SMBG 4 -6 times a d ay or 
monitor the CGM . 
• Instructed to have glucose on hand 
for hypoglycemia  
Risk  with Sensors  Prevention and Mitigation  
Risks with Sensors may include:  
• Skin irritation or reaction to adhesives  
• Bruising  
• Discomfort  
• Redness  
• Excessive bleeding due to anticoagulants  
• Bleeding  
• Pain 
• Rash  
• Infection  
• Irritation from tapes used with glucose -
sensing products  
• Raised bump  
• Appearance of a small "freckle -like" dot 
where needle was inserted  
• Allergic reaction  
• Syncopal epi[INVESTIGATOR_852302]  
• Soreness or  tenderness  
• Swelling at insertion site  
• Sensor fracture, breakage or damage  
• Minimal blood splatter associated with 
sensor needle removal  
• Residual redness associated with adhesive Prevention and mitigation include:  
• Follow the provided user guides 
for insertions and care of sensors.  
• If a sensor site becomes infected or 
inflamed, the sensor should be 
removed and another placed in a 
new location  
• Base diabetes management on 
fingerstick readings and not sensor 
glucose values.  
 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 33 OF 74 
 and or tapes  
• Scarring  
• Scab  
• Blister  
• Itchiness  
• Inflammation  
• Anxiety  
• Incorrect sensor glucose reading results in 
incorrect diabetes management  
• Participant over -treating secondary to 
alarms which can result in hyperglycemia 
or hypoglycemia  
• Anxiety associated with insertion  
Risk s with Serter  Prevention and Mitigation  
Risks with Serters may include:  
• Improper insertion may lead to device 
performance issue or hyperglycemia   Prevention and mitigation include:  
• Follow the provided user guides 
for insertions and care of Serters.  
• Training on proper use of the 
Serter and skin preparation prior to 
insertion.  
Risks with Finger Sticks  Prevention and Mitigation  
Risks with frequent  finger stick testing may 
include:  
• Potential risks associated with frequent 
meter testing of blood glucose and blood 
ketones include discomfort and 
ecchymosis at tips of fingers  
Potential risks associated with drawing blood 
include discomfort and bruising  Prevention and mitigation include:  
• Follow the provided user guides 
for use of meter with fingerstick 
testing.  
• Training on proper use of the 
meter and fingerstick testing.  
 
Risks with AHCL  Prevention and Mitigation  
Risks with AHCL include:  Prevention and mitigation include:  
• Follow the provided user guides 
for insulin pump management.  
• Training prior to study on device 
use and diabetes management 
principles and told to call with 
problems.  
• Check SMBG 4 -6 times a day.  
• Instructed to have glucose on hand 
for hypoglycemia.  
• Subjects will be asked to avoid the 
use of products contai ning 
Acetaminophen  
• If Acetaminophen is taken, 
subjects will be instructed to use 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 34 OF 74 
 • Hypoglycemia  
• Severe hypoglycemia  
• Hyperglycemia  
• DKA  
• User Entry Error  
o Patient administering boluses by 
[CONTACT_852321]  
o Patient entering false glucose 
values for any reason leading to 
hypoglycemia and hyperglycemia  
o Patient entering false BG values 
for calibration leading to 
hypoglycemia or hyperglycemia  
• Sens or failure resulting from patient 
failure to calibrate leading to 
hypoglycemia or hyperglycemia  
• Sensor over -reading resulting in 
hypoglycemia  
• Sensor under -reading resulting in 
hyperglycemia  
• Sensor missed transmission, or any other 
fault resulting in no SG value, leading to 
hyperglycemia or hypoglycemia  
• Voluntary insulin delivery (with the pump 
or with a syringe) immediately prior to 
entering Auto Mode may result in severe 
hypoglycemia despi[INVESTIGATOR_852303]  
• Patient takes ins ulin via injection while in 
Closed Loop  
• Hypoglycemia or hyperglycemia related 
to entering or exiting Closed Loop  
• Insulin over -delivery due to 
Acetaminophen  
 
 
 additional BG meter readings (they 
are not to calibrate with those 
readings) to verify their glucose 
levels.  
• If Acetaminophen is taken, 
subjects should consider exiting 
Auto M ode. 
 
Potential risks with acetaminophen may include:  
• False elevation of sensor glucose 
readings. The level of inaccuracy depends 
on the amount of acetaminophen active in 
subject’s body and may be different for 
each subject.  Prevention and mitigation inc lude:  
• Follow the user guide  
• Where possible, subjects should 
avoid the use of Acetaminophen  
• If Acetaminophen is taken, 
subjects should use additional BG 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 35 OF 74 
  meter readings (they are not to 
calibrate with those readings) to 
verify their glucose levels  
• Subjects should consider exiting 
AutoMode  
 
 581 
 Risk Assessment  582 
Based on the facts that (1) adults and adolescents with diabetes experience mild hypoglycemia 583 
and hyperglycemia frequently as a consequence of the disease and its management, (2) the study 584 
interv ention involves periodic automated insulin dosing that may increase the likelihood of 585 
hypoglycemia, and periodic automated attenuation of insulin delivery that may increase the 586 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested  in prior studies 587 
using the investigational device system in the home setting, that limit the likelihood of excessive 588 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and [ADDRESS_1185108] their origin in the Declaration of Helsinki, with 602 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  [ADDRESS_1185109] that the PID +fuzzy 607 
logic algorithm is experimental.  Therefore, an investigational device exemption (IDE) from the 608 
U.S. Food and Drug Administration (FDA) is required to conduct the study in the U S. As the [ADDRESS_1185110] to sex, gender, race, or ethnicity. All sites are 623 
experienced in either adult or pediatric endocrinology, or both, and are established research 624 
centers with proven recruitment trac k records.  625 
 626 
The recruitment goal for each site is the same (approximately 15 -16 participants per site); [ADDRESS_1185111] re presentation of individuals, there will be the following recruitment 631 
goals: 632 
• Minimum of  25% of participants entering RCT who at screening were on MDI therapy  633 
• Minimum of  25% of participants entering RCT who at screening were on Pump therapy  634 
• Minimum of  25% of participants entering RCT who at screening were on CGM therapy  635 
• Minimum of  25% of participants entering RCT who at screening were not on CGM therapy  636 
• Minimum of  25% of participants entering RCT who at screening had a POC HbA1c from 637 
7.0 - 8.5%  638 
• Minimum of  25% of participants entering RCT who at screening had a POC HbA1c from 639 
8.6 - 11.0%  640 
• Maximum of 25% of participants entering RCT who at screening had a POC HbA1c from 7.0 641 
-7.4%  642 
• Maximum of 25% of participants entering RCT who at screening were on the MiniMed 670G 643 
system  644 
 645 
Potential eligibility may be assessed as part of a routine -care examination. Prior to completing 646 
any procedures or collecting any data that are not part of usual care, written informed consent 647 
will be obtained. For potential study participants >18 years ol d, the study protocol will be 648 
discussed with the potential study participant by [CONTACT_464]. The potential study participant will 649 
be given the Informed Consent Form to read  and will be given the opportunity to ask questions.  650 
Potential study participants wi ll be encouraged to discuss the study with family members and 651 
their personal physicians(s) before deciding whether to participate in the study.  652 
 653 
For potential participants under 18 years of age, a parent/legal guardian (referred to subsequently 654 
as “parent” ) will be provided with the Informed Consent Form to read and will be given the 655 
opportunity to ask questions. Potential participants meeting the minimum age of assent will be 656 
given a Child Assent Form to read and discuss with their parents and study person nel. If the 657 
parent and child agree to participate, the Informed Consent Form and Child Assent Form will be 658 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 37 OF 74 
 signed. A copy of consent forms will be provided to the participant and their parent and another 659 
copy will be added to the participant’s study record . 660 
 661 
As part of the informed consent process, each adult participant or parent will be asked to sign an 662 
authorization for release of personal information. The investigator, or their designee, will review 663 
the study -specific information that will be collected and to whom that information will be 664 
disclosed. After speaking with the participant  and parent (if applicable) , questions will be [ADDRESS_1185112] meet all of the following inclusion criteria in order to be eligible to participate 672 
in the study:  673 
1. Type 1 diabetes mellitus (as diagnosed clinically ) with a duratio n of at least one year  674 
2. Age 14 - <[ADDRESS_1185113] will be required for all females of child -bearing potential. 680 
Participants who become pregnant will be discontinued from the study. Also, 681 
participants who during the study develop and express the  intention to become 682 
pregnant within the timespan of the study will be discontinued.  683 
4. Multiple daily injections (MDI) of insulin or an insulin pump user  [ADDRESS_1185114] be able to obtain U -100 rapid acting insulin analogues, Aspart or 685 
Lispro, for use during the study (since these are the only insulins approved for the 686 
study pump and the study is not supplying insulin)  [ADDRESS_1185115] be on a basal/bolus regimen  [ADDRESS_1185116] a minimum total daily dose (TDD) of at least eight units  689 
5. HbA1c from an approved local HbA1c point of care analyzer with an HbA1c value of 690 
7.0-11.0% 691 
6. Willingness or ability to do carbohydrate counting  692 
7. In the investigator’s judgment, participant is able to understand a nd likely to be adherent 693 
to the protocol  694 
8. For participants <18 years old, living with one or more diabetes care partners (i.e. a 695 
parent/legal guardian) of whom at least one is committed to participating in study training [ADDRESS_1185117] adequate internet access and computer system for uploading data  699 
10. For participants currently using CGM or insulin pump, willingness to discontinue 700 
personal CGM and pump when using the study CGM and pumps  (note: including 701 
implantable CGMs ) 702 
  703 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 38 OF 74 
 
 Participant Exclusion Criteria  704 
Individuals meeting any of the following exclusion criteria at screening will be ex cluded from 705 
study participation:  706 
1. Concomitant disease that influences metabolic co ntrol or HbA1c interpretation (e.g. anemia , 707 
significantly impaired hepatic function, confirmed gastroparesis, renal failure, history of 708 
adrenal insufficiency, sickle cell disease, haemoglobinopathy, or has received red blood cell 709 
transfusion or erythropoie tin within three  months prior to time of screening) or other medical 710 
condition which, in the Investigator’s opi[INVESTIGATOR_1649], may compromise patient safety, affect [ADDRESS_1185118] the participant’s ability to follow the protocol  712 
2. Oral or parenteral gl ucocorticoids taken within 1 month prior to enrollment, or plans to take 713 
oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term 714 
oral or parenteral glucocorticoids up to seven  days 715 
3. Use of antidiabetic agents other than insulin  716 
4. Use of other medications, which in the judgment of the investigator would be a 717 
contraindication to participation in the study  718 
5. One or more epi[INVESTIGATOR_116651] (hypoglycemia requiring treatment by [CONTACT_20904] 719 
person) within the previous six months  [ADDRESS_1185119] 723 
within 1 month prior to enrollment  724 
8. Current eating disorder such as anorexia or bulimia  725 
9. Currently abusing illicit drugs, marijuana, prescription drugs, or alcohol  726 
10. Visual impairm ent or hearing loss, which may compromise the participant’s ability to 727 
perform all study procedures safely, as determined by [CONTACT_093]  728 
11. One or more epi[INVESTIGATOR_171648] (DKA) requiring hospi[INVESTIGATOR_852304] 729 
months prior to screening  730 
12. Working night shifts  731 
13. Untreated celiac disease, hyperthyroidism, or hypothyroidism  732 
14. Clinically significant nephropathy (eGFR <45 mL/min) or on dialysis  733 
• Creatinine to determine eGFR must have been obtained as part of usual care within 12 734 
months prior to enrollment (if not available, at time of enrollment, screening can proceed [ADDRESS_1185120] be available prior to randomization ) [ADDRESS_1185121] physical exam (including vital signs and height and weight measurements) will be 750 
performed by [CONTACT_606945] (e.g. a physician, fellow, nurse 751 
practitioner, or a physician assistant).  752 
 753 
The following procedures w ill be performed/data collected/eligibility criteria checked and 754 
documented:  755 
• Inclusion and exclusion criteria assessed  756 
• Demographics ( socioeconomic status, date of birth, sex, race, and ethnicity)  757 
• Contact [CONTACT_3031] (retained at the site and not entered in to study database)  758 
• Medical history  759 
• Diabetes history  760 
• Concomitant medications  761 
• Physical examination to include:  762 
o Weight, height  763 
o Vital signs including measurement of blood pressure and pulse  764 
• Blood draw for:  765 
o HbA1c level measured using the DCA Vantage or similar point -of-care device or 766 
local lab (used to assess eligibility)  767 
• Urine pregnancy test for all females of child -bearing potential  [ADDRESS_1185122] approximately 1 -2 hours.  770 
 771 
 Questionnaires  772 
The following questionnaires will be completed by [CONTACT_852322] 773 
Screening, End of Period 1, and End of Period 2:  774 
• Diabetes Distress Scale  775 
• Glucose Monitoring Satisfaction Survey  776 
• Hypoglycemia Confidence  777 
• Diabetes Technology Attitudes  778 
• INSP IRE Survey  (only collected at End of Periods 1 and 2)  779 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 40 OF 74 
  780 
 Run-in Phase  781 
 Introduction  782 
There are two parts of the run -in phase:  783 
1) Pump Run -In (670G 3.0 HCL ) 784 
2) Pump+CGM Run -In (670G 3.0 HCL + Guardian Sensor (3))  785 
 786 
The length of the run -in phases may vary depending on prior experience with a 670G pump, the 787 
number of CGM hours collected during run -in, and how quickly participants become 788 
comfortable using the study pump and CGM according to Table 5. Pump and CGM Run -In 789 
Criteria  below.  790 
 791 
Table 5. Pump and CGM Run -In Criteria  792 
 Pump Run -In: 
-670G 3.0 HCL  
-Two weeks, repeat if needed  
 Pump+CGM Run -In: 
-670G 3.0 HCL  + Guardian Sensor (3)  
-Two weeks, repeat if needed  
-Auto mode off for non -670G auto mode users, PLGS on  
Pump Users  Optional   
(Complete per investigator discretion ) 
 
 Required  Must have CGM data for at least 
80% of the possible time during 
the prior [ADDRESS_1185123] 3x/day.  
 
 
Non-Pump  
Users  Required  Required  Must have CGM data for at least 
80% of the possible time during 
the prior [ADDRESS_1185124] 3x/day.  
 
 
 793 
 Pump Run -In – 670G 3.[ADDRESS_1185125] to study participants and 800 
their diabetes care partner s (for participants <18 years old). Additional topi[INVESTIGATOR_852305] 801 
are not limited to: infusion site initiation, cartridge/priming procedures, setting up the pump, [ADDRESS_1185126] the particip ant in 803 
study pump infusion site initiation and will start the participant on the study pump. For current 804 
pump users, the study pump will be programmed with the participant’s usual basal rates and [ADDRESS_1185127] and correction boluses will also be discussed. The 807 
participant’s personal pump will be removed. Participants may continue to use their personal [ADDRESS_1185128] schedule 814 
during the run -in is summarized in Table 1. Schedule of Visits and Procedures during Screening 815 
and Run -In. 816 
 817 
After completion of the Pump Run-In, participants will proceed to use the study CGM along with 818 
the study 670G 3.0 HCL  pump during the Pump+CGM Run -In period  on the same day.  819 
 820 
 Pump+CGM Run -In – 670G 3.0 HCL  + Guardian Sensor (3)  [ADDRESS_1185129] complete a two -week run -in period with the use of the study pump and 822 
CGM before being randomized into the crossover trial. During the Pump+CGM Run-In, the 823 
predictive low glucose suspend feature will be turned on and auto mo de will be turned off (i.e. 824 
manual mode). Participants who were 670G  auto mode  users at screening may use the pump in [ADDRESS_1185130] to study participants and 828 
their diabetes care partner s (for participants <18 years old) if not already provided during pump 829 
run-in. Personal pumps and CGMs will be removed during the Pump+CGM Run-In period as [ADDRESS_1185131] seven days (7±2 837 
days), followed by a clinic visit after 14 days (14+3 days) for each run -in period.  If any run -in [ADDRESS_1185132] 841 
schedule during run -in. Contacts may be substituted for a visit. Additional contacts or visits may 842 
be done as needed.  843 
 844 
 Run-In Assessments  845 
Device data will be downloaded by [CONTACT_852323] t during Run -In. 846 
 847 
Successful completion of the Pump Run-In is per investigator assessment.  848 
 849 
Successful completion of the Pump+CGM Run-In requires that CGM data be collected for at [ADDRESS_1185133] 8 0% of the possible time during the prior [ADDRESS_1185134] three blood glucose meter tests per day. If this is not achieved the Pump+CGM Run-In may 852 
be repeated once.  If the participant does not complete the Pump+CGM Run -In the second time, [ADDRESS_1185135] not proceed to randomize an 863 
individual until they are convinced that the participant is eligible and will acc ept assignment 864 
to either of the two treatment orders . 865 
 866 
 Randomization Visit  867 
The randomization visit is expected to begin  on the same day the Pump+CGM Run -In period is 868 
completed. Eligibility criteria from screening will be reviewed again and if the participa nt is no 869 
longer eligible based on these criteria, the participant will be dropped from the study.  870 
 871 
 Randomization  872 
Eligible participants will be randomly assigned to use the study pumps  (along with the study 873 
CGM) in one of the following orders:  874 
1. 670G 3.0 HCL  during  Period 1 then switch to the 670G 4.0 AHCL during  Period 2 ; or 875 
2. 670G 4.0 AHCL during  Period 1 then switch to the 670G 3.0 HCL  during  Period 2  876 
 877 
Participant randomization assignment is determined after the Randomization Visit data on the 878 
study websi te are entered. The data from this visit and where applicable, prior visits, are assessed 879 
to verify eligibility prior to the randomization process being completed.  880 
 881 
 HbA1c, C -peptide, and Glucose  882 
After the participant is randomized , a blood sample will be d rawn to send to the central laboratory 883 
for baseline HbA1c determination to be used in outcome analyses and may be either venous or 884 
capi[INVESTIGATOR_1396]. Blood samples will also be drawn to send to the central lab for random C -peptide and 885 
glucose levels.  886 
 887 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 43 OF 74 
 
 Crossover Trial  888 
 889 
 Study Procedures and Schedule during the Crossover Trial  890 
 AID System Training  891 
Automated insulin delivery (AID) training can occur on the same day or extend up to one 892 
additional day if needed from randomization.  AID training includes auto mode training  and will 893 
be provided at the beginning of  each crossover period.  894 
 895 
The participant and care partner will be trained by [CONTACT_852324] 896 
including meal announcement, meal bolusing, and exercise.  For participants <18 years old, the 897 
diabetes care partner will be trained on severe hypoglycemia emergency procedures including 898 
removal of the study pump and administration of glucagon, and on all other training procedures.  899 
 900 
Participants will be provided with Hypoglycemia, Hyperglycemia, and Ketone Guidelines for 901 
when their glucose levels are  ≥250 mg/dL (13.9 mmol/L) for more than two hours, or  ≥300 902 
mg/dL (16. 7 mmol/L) for over 1 hour or >400 mg/dL (22.2 mmol/L) at any time or <70 mg/dL 903 
(3.9 mmol/L) or ketones ≥0.6 mmol/L.  904 
 905 
Study team members will train the participant and care partner in performing specific tasks 906 
including the following:  907 
• The study team will confirm the pump parameters entered in the system  908 
• When not to use or rely on auto mode particularly during significant illness  909 
• CGM calibration instructions  910 
• Meal bolus procedures  911 
• What to do when exercising while using the system.  912 
• The participant and care partner will be assessed for understanding how to react to 913 
safety/alert notifications  914 
• Participants will be reminded to perform fingerstick blood glucose measurements in 915 
accordance with the labeling of the study CGM device  916 
• Participants will be instructed when to contact [CONTACT_852325] [ADDRESS_1185136] during the study  918 
 919 
Study staff will discuss the visit schedule with the participant and will make arrangements with 920 
the participant for the contacts. If the participant cannot be reached, the participant’s other [ADDRESS_1185137] methods will be utilized.  922 
 923 
 Home Use of AID System during Study Period 1  924 
After AID training has been completed, participants will proceed with home use of the AID 925 
system (meaning free -living use at work, home, etc.) during Study Period 1 with either the 670G 926 
3.0 HCL  or 670G 4.0 AHCL pump as determined by [CONTACT_852326]. The predictive 927 
low glucose suspend feature will be turned on.  Participants starting with the 670G 4.0 AHCL 928 
pump will return the 670G 3.0 HCL pump used during Run -In. 929 
 930 
The system will initially be used with aut o mode deactivated (except for 670G  auto mode  users 931 
at screening who may activate auto mode  if using the 670G 3.0 HCL pump ) until participants are 932 
contact[INVESTIGATOR_530] 6 -10 days into Study Period 1 with instructions to ensure  auto mode  is initialized . 933 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 44 OF 74 
 Participants wi ll also be instructed to ensure a new sensor is inserted 24 hours prior to initializing 934 
auto mode. Participants will then continue using the AID system for 12 weeks after auto mode is 935 
initialized. Participants will be expected to use auto mode at all times  at home with some 936 
exceptions (e.g. times of illness, acetaminophen use).  937 
 938 
 Home Use of AID System during Study Period 2  939 
There will be no washout period.  Participants will proceed with home use of the AID system 940 
(meaning free -living use at work, home, etc.)  during Study Period [ADDRESS_1185138] day of Crossover Period 2.  943 
 944 
The system will initially be used with auto mode deactivated (except for 670G  auto mode  users 945 
at screening who may activate auto mode  if using the 670G 3.0 HCL pump ) until participants are 946 
contact[INVESTIGATOR_530] 6 -10 days into Study Period 2 with instructions to ensure  auto mode  is initialized . 947 
Participants will also  be instructed to ensure a new sensor is inserted 24 hours prior to initializing 948 
auto mode. Participants will then continue using the AID system for 12 weeks after auto mode is 949 
initialized. Participants will be expected to use auto mode at all times at hom e with some 950 
exceptions (e.g. times of illness, acetaminophen use).  [ADDRESS_1185139] Schedule during Study Periods 1 and 2  953 
During each of the two study periods, visits and contacts will be scheduled as outlined below. 954 
Additional contacts or visits m ay occur as needed:  955 
• Study Period begins  956 
o 6-10 days – participants will be contact[CONTACT_852327] 957 
initialized  958 
• Auto mode is initialized (remaining visits and contacts are relative to the day auto mode 959 
is confirmed to be initialized  by [CONTACT_6624] ) [ADDRESS_1185140]  (Contact [CONTACT_852328])   [ADDRESS_1185141]  (±2 days)  = 3-7 days  (Contact [CONTACT_852329] p hone)  962 
o 2-week visit (±4 days)  = 10-[ADDRESS_1185142] (±4 days)  = 24-32 days  964 
o 6-week visit (±4 days)  = 38-[ADDRESS_1185143] (±4 days)  = 59-67 days  966 
o 12-week visit /contact  (+7 days)  = 84-91 days  (end of study period)  967 
 968 
The goal will be for all participants to  complete all scheduled visits.  However, participants who 969 
(because of unforeseen circumstances) are unable or unwilling to return for all follow -up visits 970 
will be permitted to return for key visits only as an alternative to withdrawal from t he study.  971 
When a participant is placed into this status, missed visits will not be recorded as protocol 972 
deviations (since they would not be recorded as protocol deviations if the participant was 973 
dropped from the study).  974 
 975 
 Procedures During  Study Periods  976 
[IP_ADDRESS]  Procedures performed during each contact  977 
• The participant will be asked to upload device data for study staff review  978 
• Assessment of compliance with study device use  979 
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 45 OF 74 
 • Answer questions about using the AID system  980 
• Assessment of adverse events, adverse device effect s, and device issues  981 
• Review of glycemic control  982 
 983 
[IP_ADDRESS]  Procedures performed during each follow -up visit  984 
• Assessment of compliance with study device use  985 
• Retraining on system use as needed  986 
• Assessment of adverse events, adverse device effects, and device issues  987 
• Download of AID system and study meter data (BG and ketone data) 988 
• All study blood glucose  and ketone  meters will be quality control ( QC) tested with 989 
the available concentration(s) of control solution if the meters are  available during all 990 
office visi ts 991 
• Venous or capi[INVESTIGATOR_852306] a blood sample to send to the central laboratory for 992 
HbA1c determination at the beginning and end of Periods 1 and 2  993 
• Urine pregnancy test for females of child -bearing potential at the beginning of Period 994 
2  995 
• Participant weight, height, and blood pressure will be measured at the beginning and 996 
end of Periods 1 and 2.  997 
• Completion of questionnaires at the end of Periods 1 and 2   998 
• Review of glycemic control  999 
At the Final Visit, participants will return study systems  and be placed back on their pre -study 1000  
insulin delivery method and glucose monitoring method. If the participant desires a change (e.g. 1001  
prior MDI user who wants to use a pump, non -CGM user who wants  to use CGM), this will be 1002  
handled as part of usual care . The Final Visit  may be completed in -person  in clinic or in an 1003  
alternate location such as the participant’s home.  If this is not possible, the study visit may occur [ADDRESS_1185144] and an arrangement will be made between site staff and 1008  
the participant to return all required study devices  either in -person or via mail . 1009  
 1010  
[IP_ADDRESS]  Setpoint a djustments during 670G  4.0 AHCL use  1011  
All participants in the 670G 4.0 AH CL arm will start with an auto mode target glucose set point 1012  
of 120 mg/dL  (6.7 mmol/L) . At the auto mode initiation contact, participants will be reminded to  1013  
obtain  an overnight fingerstick  blood glucose measurement  (between 2 -3AM) for 2 -3 nights 1014  
following auto mode initiation and if SMBG is <70 mg/dL to treat  with carbohydrate , 1015  
discontinue closed loop mode,  and notify the  investigator or designee  the next day for advice . 1016  
Study staff will inquire about  the fingerstic ks and reinforce the importance of these fingersticks 1017  
at both the 24 -hour and 3 -7 day follow -up phone calls . At the 2 -week assessment visit the target 1018  
glucose set point should be lowered to 100 mg/dL  (5.6 mmol/L)  if the participant meets the [ADDRESS_1185145] 1020  
no other clinical reason not to reduce the setpoint : 1021  
• No severe hypoglycemia; AND  1022  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 46 OF 74 
 o No more than 1% of sensor glucose readings <54 mg/dL (3.0 mmol/L) for the 1023  
24-hour time period based on review of CGM download AND no sensor 1024  
glucose readings less than 54 mg/dL from Midnight to 6AM; OR  1025  
o No more than 3% of sensor glucose readings less than 70 mg/dL (3.9 mmol/L) 1026  
for 24 hours  1027  
 1028  
If the participant does not meet these criteria the setpoint should remain at 120 mg/dL  (6.7 1029  
mmol/L)  and the participant should be reevaluated at 4, 6, and 9 weeks to see if the setpoint can 1030  
be reduced to 100 mg/dL  (5.6 mmol/L)  using the same criteria.  When the setpoint is lowered, 1031  
the same re quirement  as above will be provided regarding overnight fingersticks.  1032  
 1033  
The setpoint may be adjusted at any time if clinically appropriate per investigator’s opi[INVESTIGATOR_1649].  [ADDRESS_1185146] th e participant has with the site for 1047  
significant protocol -related issues/questions outside the visit schedule. 1048  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 47 OF 74 
 
 Study Devices  and Safety  1049  
 1050  
 Description of the Study  Device s 1051  
 Insulin Pump s 1052  
One insulin pump used in the study is the Minimed 670G 3.0 HCL  insulin pu mp, which is an 1053  
FDA -approved  and CE -marked  device system with no changes to its hardware or firmware 1054  
components (MMT -1780 in the [LOCATION_002], MMT -1781 and MMT -1782 outside the United 1055  
States). The 670G 4.[ADDRESS_1185147] 1056  
(MMT -1740 in the [LOCATION_002], MMT -1741 and MMT -1742 outside the [LOCATION_002]). The 1057  
670G 4.0 AHCL pump is the same as the 670G 3.0 HCL  pump except the AHCL pump includes 1058  
the Fuzzy Logic algorithm software.  1059  
 1060  
 Continuous Glucose Monitoring  1061  
The study sensor is the Guardian Sensor (3) (MMT -7020). This is an FDA -approved and CE - 1062  
marked device system with no changes to its hardware or firmware components. The CGM 1063  
sensor will be connected to a Guardian Link (3) transmitter (MMT -7811) an d the sensor will be 1064  
replaced in accordance with manufacturer labeling (e.g. at least once every seven days).  This 1065  
device is not investigational.  1066  
 1067  
 Blood Glucose Meter and Strips  1068  
Blood glucose levels will be measured and the CGM device will be calibrated using the Contour 1069  
Next Link 2.4 meter (MMT -1152 or MMT -1352) (or equival ent meter, such as the Contour plus  1070  
Link)  and test strips in accordance with manufacturer labeling.  1071  
 1072  
 Ketone Meter and Strips  1073  
Blood ketone levels will be measured using the Abbott Precision Xtra  (or equivalent meter, such 1074  
as the Optium Neo)  meter and strips in accordance with manufacturer labeling. The blood 1075  
glucose meter component of ketone meters will not be us ed. 1076  
 1077  
 Study Device Accountability Procedures  1078  
Good clinical research practice requires that investigators and research teams ensure accurate 1079  
accountability for any investigational device used in a research trial. It is expected that all 1080  
investigational devic es or approved devices used outside their approved intended use will be 1081  
used in the manner intended during the study, that they will be stored under appropriately 1082  
controlled conditions, and that they will be used only by (on) participants who have consente d to [ADDRESS_1185148] be strictly accounted for and will not be shipped to any site unless 1087  
all of the necessary approvals (e.g. Regulatory, IRB/EC) have been received. This includes 1088  
keepi[INVESTIGATOR_116652]:  1089  
1. Center receipt and inventory management  1090  
2. Storage  1091  
3. Participant Disbursement   1092  
4. Return (by [CONTACT_852330]) and/or disposal  1093  
 1094  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 48 OF 74 
 US: Investigational devices or approv ed devices used outside their approved intended use will be 1095  
labeled “Investigational Device” in a ccordance with 21 CFR Part 812. 140.  1096  
EMEA: In accordance with the MDD directive, the investigational devices for EMEA will be 1097  
labeled “Exclusively for Clinical  Investigations”  [ADDRESS_1185149] of the study the investigational center staff will account for, and document, 1100  
the Device accountability procedures as detailed in the site procedures manual.  1101  
 1102  
 Blood Glucose Meter Testing  1103  
• Participants will be provided with instructions to perform quality control (QC) testing per [ADDRESS_1185150] strips, and control solution if a meter fails QC testing at 1106  
home.  1107  
• A tested meter will not be used in a study if it does not read within the target range at 1108  
each concentration per manufacturer labeling.  1109  
• Participants will be reminded to use the study blood glucose meter for all fingerstick 1110  
blood glucose measurements  1111  
• Partici pants will be asked to perform fingerstick blood glucose measurements in 1112  
accordance with the labeling of the study CGM device.  1113  
 1114  
 Blood Ketone Testing  1115  
• Participants will be provided with instructions to perform quality control (QC) testing per [ADDRESS_1185151] strips, and control solution if a meter fails QC testing at 1118  
home.  1119  
• All study blood ketone meters will be QC tested with the available concentration(s) o f 1120  
control solution if the meter is available during all office visits. A tested meter will not be 1121  
used in a study if it does not read within the target range at each concentration per 1122  
manufacturer labeling.  1123  
• Participants will be instructed on how to perfor m blood ketone testing  1124  
• Participants will be given guidelines for treatment of elevated blood ketones  1125  
 1126  
 Safety Measures  1127  
 CGM Calibration  1128  
Throughout the study, participants will be instructed to calibrate the study CGM in accordance 1129  
with manufacturer labeling.  1130  
 1131  
 Pump Failure  1132  
In the event of a pump failure, the participant will be instructed to use their personal insulin 1133  
regimen until the problem can be resolved. Re portable events are described in Chapter 8: . 1134  
 1135  
 Hypoglycemia Threshold Alarm and Safety Protocol   1136  
During the course of the study, participants will be permitted to change the low glucose threshold 1137  
alarm setting , but it is recommend to set it t o 70 mg/dL (3.9 mmol/L). Participants will be 1138  
encouraged to be consistent with their use of any such features between the two periods of the 1139  
crossover study.  1140  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 49 OF 74 
  1141  
If a participant receives a CGM hypoglycemia threshold alarm or notes that the CGM glucose is 1142  
below the hypoglycemia threshold alarm value, confirmatory fingerstick testing will be 1143  
performed if required by [CONTACT_852331] d to treat 1144  
hypoglycemia with ~[ADDRESS_1185152] -acting oral glucose.  1145  
 1146  
 Hyperglycemia Threshold Alarm and Safety Protocol   1147  
During the course of the study, participants will be permitted to change the high glucose 1148  
threshold alarm setting , but it is recommend to set it to 300 mg/dL (16.7 mmol/L). Participants 1149  
will be encouraged to be consistent with th eir use of any such features between the two periods 1150  
of the crossover study.  1151  
 1152  
If a participant receives a CGM hyperglycemia threshold alarm or notes that the CGM glucose is 1153  
above the hyperglycemia threshold alarm value, confirmatory fingerstick testing wil l be 1154  
performed if required by [CONTACT_113462].  1155  
 1156  
During the time period when auto mode is operational and active, if a participant’s CGM reading 1157  
is >300 mg/dL  (16.7 mmol/L)  for over one hour or ≥400 mg/dL (22.2 mmol/L) at any point, the 1158  
participant will be instructed to take the following steps:  1159  
• Perform a blood glucose meter check.  1160  
o If the blood glucose is >300 mg/dL  (16.7 mmol/L) , check for blood ketones with 1161  
the study ketone meter.  1162  
▪ If the ketone level is >0.6 mmol/L, contact [CONTACT_852332] 1163  
instructions, which may include replacing the insulin infusion set.  1164  
 1165  
 Safety Measures Specific to AID system use  1166  
[IP_ADDRESS]  Insulin Dosing  [ADDRESS_1185153] 1168  
be performed using the pump bolus calculator.  1169  
 1170  
 Safety Measures for Open -Loop (Manual Mode) CGM Use  1171  
These measures apply when the AID system (auto mode) is not being used or is not 1172  
communicating with the CGM device.  1173  
 1174  
[IP_ADDRESS]  Hypogly cemia Safety Protocol  1175  
If a participant receives a CGM hypoglycemia threshold or predictive alarm or notes that the 1176  
CGM glucose is below the hypoglycemia threshold alarm value, confirmatory fingerstick testing 1177  
will be performed if required by [CONTACT_606948] a nd the participant will be instructed to treat 1178  
hypoglycemia with ~[ADDRESS_1185154] -acting oral glucose.  1179  
 1180  
[IP_ADDRESS]  Hyperglycemia Safety Protocol  1181  
If a participant receives a CGM hyperglycemia threshold alarm or notes that the CGM glucose is 1182  
above the hyperglycemia threshold alarm value, confirmatory fingerstick testing will be 1183  
performed if required by [CONTACT_852333] g. 1184  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 50 OF 74 
 
 Laboratory Testing and Questionnaires  1185  
 1186  
 Laboratory Testing  1187  
HbA1c:  1188  
• Performed locally at the Screening visit.  1189  
• Collected for central lab analys is at Randomization, and at the beginning and end of each 1190  
study pe riod during the crossover trial . Final HbA1c may also be collected for participants 1191  
who withdraw from the study.  1192  
 1193  
Random C -Peptide and Glucose:  1194  
• Collected at Randomization for central lab ana lysis  1195  
 1196  
Urine Pregnancy:  1197  
• Performed locally for females of child -bearing potential at Screening and at the beginning of [ADDRESS_1185155] been obtained within 12 months prior to 1203  
enrollment  (if not available, at time of enrollment, screening can proceed but it must be available 1204  
prior to randomization ). 1205  
 1206  
 Questionnaires  1207  
The following questionnaires will be completed at Screening and at the end of each period 1208  
during the crossover trial (except that the INSPI[INVESTIGATOR_852307] 1209  
Screening) . Final questionnaires may also be collected for participants who withdraw from the [ADDRESS_1185156] Measured / Relevant Points  
Diabetes Distress Scale  Gold standard measure for understanding distress symptoms related to 
diabetes. A recently validated version for adults with T1D , but will  also be 
administered to adolescents (17  items; 6 min)  
Glucose Monitoring 
Satisfaction Survey  This recently validated survey is an outgrowth of DirecNet and JDRF 
CGM surveys; evaluates treatment satisfaction and burden. Administered 
to all participants (15 items; 4 min)  
Hypoglycemia Confidence  Includes 8 different common situations where hypoglycemia occurs (e.g., 
physical activity, driving) and evaluates level of confidence in those 
situations (8 items; 3 min)  
Diabetes Technology Attitudes  Subjective  questions about attitudes related to diab etes technologies and 
devices (5  items; 3 min)  
INSPI[INVESTIGATOR_852308]. Adult 
survey has 22  items; adolescent version 17  items. (6 -8 mins ; only 
collected at end of periods 1 and 2 ) 
1217  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 51 OF 74 
 
  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_007] 1218  
Rules  1219  
 1220  
 Adverse Events  1221  
 Definitions  1222  
Adverse Event (AE ): Any untoward medical occurrence in a study participant, irrespective of the 1223  
relationship between the adverse event and the device(s) under investigation  (see Section 8.1.2  1224  
for reportable adverse events for this protocol).  1225  
 1226  
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  1227  
• Results in death.  1228  
• Is life -threatening; (a non -life-threatening event which, had it been more severe, [ADDRESS_1185157] become life -threa tening, is not necessarily considered a serious 1230  
adverse event).  1231  
• Requires inpatient hospi[INVESTIGATOR_1081].  1232  
• Results in persistent or significant disability/incapacity or substantial disruption of [ADDRESS_1185158] n ormal life functions (sight threatening).  1234  
• Is a congenital anomaly or birth defect.  1235  
• Is considered a significant medical event by [CONTACT_265028] 1236  
judgment (e.g., may jeopardize the participant or may require medical/surgical 1237  
intervention to  prevent one of the outcomes listed above).  [ADDRESS_1185159] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_1185160], probl em, or death was not previously identified in nature, severity, or degree of 1242  
incidence in the investigational plan or application (including a supplementary plan or 1243  
application), or any other unanticipated serious problem associated with a device that rela tes to 1244  
the rights, safety, or welfare of participants (21 CFR 812.3(s)).  [ADDRESS_1185161] (ADE):  Any untoward medical occurrence in a study participant which [ADDRESS_1185162] contributed (Note that an Adverse  1248  
Event Form is to be completed in addition to a Device Deficiency or Issue Form unless excluded 1249  
from reporting as defined in Section 8.2). For reporting purposes, the ADE definition will be 1250  
used to define reportable AEs for the  commercially available system (670G  3.0) as well as the 1251  
investigational system (AHCL).  1252  
 1253  
Device Complaints  and Malfunctions : A device complication or complaint is somet hing that 1254  
happens to a n investigational  device or related to device performance, whereas an adverse event 1255  
happens to a participant. A device complaint may occur independently from an AE, or along 1256  
with an AE. An AE may occur without a device complaint or th ere may be an AE related to a 1257  
device complaint. A device malfunction is any failure of a device to meet its performance 1258  
specifications or otherwise perform as intended.  Performance specifications include all claims 1259  
made in the labeling for the device.  The intended performance of a device refers to the intended 1260  
use for which the device is labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, [ADDRESS_1185163] medical occurrence that 1265  
meets one of the following criteria:  1266  
1. An SAE  1267  
2. An ADE as defined in  Section  8.1.1 , unless excluded  from reporting in Sectio n 8.2 1268  
3. An AE as defined in  Section  8.1.1  occurring in association with a study procedure  1269  
4. An AE as defined in  Section  8.1.1  which leads to discon tinuation of a study device for two or 1270  
more hours  1271  
5. Hypoglycemia meeting the definition of severe hypoglycemia as defined below   1272  
6. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, hyperglycemia or [ADDRESS_1185164].  Skin reactions from sensor  adhesive  1277  
placement are only reportable if severe and/or required treat ment.   1278  
 1279  
Pregnancy occurring d uring the study will be reported as an AE (see Section 8.3). 1280  
 1281  
All reportable AEs —whether volunteered by [CONTACT_2299], discovered by [CONTACT_3462] [ADDRESS_1185165], or other means — 1283  
will be reported on an AE form online. Each AE form is reviewed by [CONTACT_852334] 1284  
assess safety and to verify the coding and  the reporting that is required.  1285  
 1286  
[IP_ADDRESS]  Hypoglycemic Events  [ADDRESS_1185166] is only reportable as an adverse 1288  
event when the following definition for severe hypog lycemia is met:  the event required 1289  
assistance of another person due to altered consciousness, and required another person to actively 1290  
administer carbohydrate, glucagon, or other resuscitative actions.  This means that the participant 1291  
was impaired cognitivel y to the point that he/she was unable to treat himself/herself, was unable 1292  
to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure 1293  
or loss of consciousness.  These epi[INVESTIGATOR_852309] 1294  
induce seizure or loss of consciousness.  If plasma glucose measurements are not available during 1295  
such an event, neurological recovery attributable to the restoration of plasma glucose to normal 1296  
is considered sufficient evidence that the event w as induced by a low plasma glucose 1297  
concentration . 1298  
 1299  
[IP_ADDRESS]  Hyperglycemic/Ketotic Events  [ADDRESS_1185167] is only reportable as an adverse 1301  
event when one of the following four  criteria is met:   1302  
• the event involved DKA, as de fined by [CONTACT_3467] 1303  
(DCCT) and described below  1304  
• evaluation or treatment was obtained at a health care provider facility for an acute event 1305  
involving hyperglycemia or ketosis  1306  
• blood ketone level ≥1.0 mmol/L and communication occurred with a health care provider 1307  
at the time of the event  1308  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 53 OF 74 
 • blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 1309  
provider  1310  
 1311  
Hyperglycemic events are classified as DKA if the following are present:  1312  
• Symptoms such as polyuria, polydipsia, nausea, or vomiting;  1313  
• Serum ketones >1.5 mmol/L or large/moderate urine ketones;  1314  
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and  1315  
• Treatment provided in a health care facility  [ADDRESS_1185168] been caused 1320  
by [CONTACT_19911].   Note that this asses sment will be made for both the investigational device 1321  
(AHCL system) and the commercially available system (670G  3.0). 1322  
 1323  
To ensure consistency of adverse event causality assessments, investigators should apply the 1324  
following general guideline when determinin g whether an adverse event is related:  1325  
• Unrelated: The AE is clearly not related to a study drug/device and a likely alternative 1326  
etiology exists such as an underlying disease, environmental or toxic factors or other 1327  
therapy.  1328  
• Unlikely Related: The AE does no t follow a reasonable temporal sequence during or 1329  
after use of study drug/device and a more likely alternative etiology exists such as an 1330  
underlying disease, environmental or toxic factors, or other therapy.  1331  
• Possibly Related: The AE occurred in a reasonable time during or after use of study 1332  
drug/device; but could be related to another factor such as an underlying disease, 1333  
environmental or toxic factors, or other therapy; and there is a possible, though weak, 1334  
scientific basis for establishing a caus al association between the AE and the study 1335  
drug/device.  1336  
• Probably Related: The AE occurred in a reasonable time during or after use of study 1337  
drug/device; is unlikely to be related to another factor such as an underlying disease, [ADDRESS_1185169] ors, or other therapy; and there is a plausible, though not 1339  
strong, scientific basis for establishing a causal association between the AE and the study 1340  
drug/device.  1341  
• Definitely Related: The AE occurred in a reasonable time during or after use of study 1342  
drug/ device; cannot be explained by [CONTACT_3468], 1343  
environmental or toxic factors, or therapy; and there is a strong scientific basis for 1344  
establishing a causal association between the AE and the study drug/device.  1345  
• Not Assessable:  Causality of an adverse event cannot be judged because information is 1346  
insufficient or contradictory, and which cannot be supplemented or verified.  1347  
 1348  
 Intensity of Adverse Event  1349  
The intensity of an adverse event will be rated on a three point scale: (1) mild , (2) moderate, or 1350  
(3) severe. It is emphasized that the term severe is a measure of intensity: thus a severe adverse 1351  
event is not necessarily serious. For example, itching for several days may be rated as severe, but 1352  
may not be clinically serious.  1353  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 54 OF 74 
 • MILD:  Usually transient, requires no special treatment, and does not interfere with the 1354  
participant’s daily activities.  1355  
• MODERATE: Usually causes a low level of inconvenience or concern to the 1356  
participant and may interfere with daily activities, but is usually  ameliorated by [CONTACT_3469] 1357  
therapeutic measures.  1358  
• SEVERE: Interrupts a participant’s usual daily activities and generally requires 1359  
systemic drug therapy or other treatment.  1360  
 1361  
 Coding of Adverse Events  1362  
Adverse events will be coded using the MedDRA dictionary. The Medical Monitor will review 1363  
the investigator’s assessment of causality and may agree or disagree. Both the investigator’s and 1364  
Medical Monitor’s assessments will be recorded. The Medical Monitor will have the final say in 1365  
determining the cau sality.  1366  
 1367  
 Outcome of Adverse Event  1368  
The outcome of each reportable adverse event will be classified by [CONTACT_3470]:  1369  
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without [ADDRESS_1185170] the AE/SAE stop date.  1371  
• RECOVERED/RESOL VED WITH SEQUELAE – The event persisted and had stabilized [ADDRESS_1185171] the AE/SAE stop date.  1373  
• FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event 1374  
that was the cause of death should be re ported as fatal.  AEs/SAEs that were ongoing at 1375  
the time of death; however, were not the cause of death, will be recorded as “resolved” at 1376  
the time of death.  1377  
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined 1378  
as the event was ongoing with an undetermined outcome.  1379  
 An ongoing outcome will require follow -up by [CONTACT_3471] 1380  
outcome of the AE/SAE.  1381  
 The outcome of an ongoing event at the time of death that was not the cause of death, 1382  
will be updated and recorded as “res olved” with the date of death recorded as the stop 1383  
date.  1384  
• UNKNOWN – An unknown outcome is defined as an inability to access the participant or 1385  
the participant’s records to determine the outcome (for example, a participant that was lost 1386  
to follow -up). 1387  
If any  reported adverse events are ongoing when a participant completes the study (or 1388  
withdraws), adverse events classified UADEs will be followed until they are either resolved, [ADDRESS_1185172] has completed all 1390  
applicable study visits/contacts. For all other adverse events, data collection will end at the 1391  
time the participant completes the study. Note: participants should continue to receive 1392  
appropriate medical care for an adverse event after their participat ion in the study ends.  1393  
 1394  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 55 OF 74 
 
 Reportable Device Issues  1395  
All UADEs and ADEs as defined in Section 8.1.1  will be reported on both a device issue form 1396  
and AE form, except fo r skin reactions from CGM sensor placement or pump infusion set 1397  
placement that are not severe and/or require  treatment . [ADDRESS_1185173] not been met:  1402  
• CGM sensor lasting fewer days than expected per manufacturer  1403  
• CGM tape adherence issues  1404  
• Pump infusion set occlusion (including tubing and cartridge) not leading to ketosis ≥0.6 1405  
mmol/L or in the absence of checking for blood ketones, blood glucose >350 mg/dL 1406  
(19.4 mmol/L); and not requiring an intervention other than replacing the tubing and/o r 1407  
cartridge  1408  
• Battery lifespan deficiency due to inadequate charging or extensive wireless communication  1409  
• Intermittent device component disconnections/communication failures not requiring 1410  
system replacement or workaround/resolution not specified in user guide /manual.  1411  
• Device issues clearly addressed in the user guide manual that do not require additional [ADDRESS_1185174] be 1420  
reported to the Coor dinating Center within 24 hours  of the sit e becoming aware of the event. 1421  
This can occur via phone or emai l, or by [CONTACT_852335] 1422  
device issue form if applicable. If the form is not initially completed, it should be competed as 1423  
soon as possible after there is sufficient information to evaluate the event.  All other repor table 1424  
ADEs and other reportable AEs should be submitted by [CONTACT_852336] 1425  
seven  days of the site becoming aware of the event.  1426  
 1427  
The Coordinating Center will notify all participating investigators of any adverse event that is 1428  
serious, r elated, and unexpected. Notification will be made within 10 days after the Coordinating 1429  
Center becomes aware of the event.  1430  
 1431  
Each principal investigator [INVESTIGATOR_3411] -related adverse events and 1432  
abiding by [CONTACT_852337]/her Institutional Review Board or 1433  
Ethics Committee.  1434  
 1435  
Upon receipt of a UADE report, the Coordinating Center will investigate the UADE and if 1436  
indicated, report the results of the investigation to the sites’ IRBs, and the FDA withi n ten 1437  
working days of the Coordinating Center becoming aware of the UADE per 21CFR 812.46(b) 1438  
(2). The Medical Monitor must determine if the UADE presents an unreasonable risk to [ADDRESS_1185175] receipt notice of the UADE.  1443  
 1444  
Device malfun ctions will be handled by [CONTACT_5081] .  1445  
 1446  
 Stoppi[INVESTIGATOR_2121]  1447  
 Participant Discontinuation of Investigational  Device  1448  
Rules for discontinuing investigational  device use are described below.  1449  
 1450  
• The investigator believes it is unsafe for the participant to continue on the intervention. 1451  
This could be due to the development of a new medical condition or worsening of an 1452  
existing condition; or participant behavior contrary to the indications for use o f the device 1453  
that imposes on the participant’s safety  1454  
• The participant requests that the treatment be stopped  1455  
• Two distinct epi[INVESTIGATOR_3414]  (as defined in section 8.1.2 ) unrelated to infusion set 1456  
failure  1457  
• A single epi[INVESTIGATOR_66677] (as defined in  section [IP_ADDRESS]) or DKA  (as 1458  
defined in section [IP_ADDRESS] ) for which use of the investigational device (AHCL system) is 1459  
considered by [CONTACT_852338] (ie, there 1460  
is not another  plausible  assignable  cause) in the absence of a device malfunction (e.g., 1461  
software bug) for which the automated insulin delivery algorithm is temporarily or 1462  
permanently discontinued for all subjects  1463  
• Two distinct severe hypoglycemia events (as defined in Section [IP_ADDRESS] ) 1464  
 1465  
Even if the investigational device system is discontinued, the participant will be encouraged to 1466  
remain in the study through the final study visit.  If the investigational device (ie . AHCL system) 1467  
is discontinued for safety reasons, the investigator with concurrence of the Medical Monitor can 1468  
switch the participant to either use the 670G 3.0 HCL  system in closed loop (if  the participant  1469  
entered the trial on 670G 3.0 HCL using closed loop ) or to 670G  3.0 HCL system but in open 1470  
loop only . 1471  
 1472  
 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  1473  
In the case of a n unanticipated  system malfunction  of the investigational device  resulting in a 1474  
severe hypoglycemia  or DKA  event ( both defined in Section 8.1), use of the investigational  1475  
device system will be suspended while the problem is dia gnosed.  1476  
 1477  
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1478  
study device requires stoppage of device use for safety reasons (e.g. product recall). The affected 1479  
study activities may resume if the underlying pro blem can be corrected by a protocol or system 1480  
modification that will not invalidate the results obtained prior to suspension.  1481  
 1482  
The study Medical Monitor will be informed of all adverse events and adverse device events that 1483  
are reported during the study and  will review compi[INVESTIGATOR_27985] 1484  
(generally timed to the review of compi[INVESTIGATOR_418081]). The Medical Monitor may [ADDRESS_1185176] (DSMB) will  review compi[INVESTIGATOR_352700] 1490  
intervals (typi[INVESTIGATOR_852310]). In addition, the DSMB will review all DKA and severe 1491  
hypoglycemia events i rrespective of relatedness to study device use, and all serious events 1492  
(including UADEs) related to the study device use at the time of occurrence.  The DSMB also [ADDRESS_1185177] modifications to the study protocol or suspension or 1495  
outright stoppage of the study if deemed necessary based on the totality of safety data available.  1496  
Details regarding DSMB review will be documented in a separate DSMB  document.  1497  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 58 OF 74 
 
 Miscellaneous Considerations  1498  
 1499  
 Drugs Used as Part of the Protocol  1500  
U-100 rapid acting insulin analogues, Aspart or Lispro, will be used during the study since these 1501  
are the only insul ins approved for the study pump s. 1502  
 1503  
 Collection of Medical Conditions and Medications  1504  
Pre-Existing Condition:  Any medical condition that is either present at screening, a chronic [ADDRESS_1185178] the participant’s health during the course of the 1506  
study (e.g., pri or myocardial infarction or stroke).  1507  
Medical Conditions during the study:  In addition to conditions meeting the reporting 1508  
requirements for an adverse event or  device issues as described in S ection 8.1 and Section 8.2, 1509  
the following medical conditions should also be reported: (1) new dia gnosis of a chronic disease 1510  
(not pre sent at the time of enrollment);  and (2) any medical condition that could affect the 1511  
participant’s ability to carry out any aspect of the protocol or could affect an outcome 1512  
assessment.  1513  
Medications:  All medication for the treatment of chronic pre -existing condi tions, medical 1514  
conditions, and/or adverse events that the participant is currently taking at screening and during 1515  
the course of t he study should be recorded. Nutraceuticals and preventative treatment also should 1516  
be recorded.  1517  
 Prohibited Medications, Treatme nts, and Procedures  1518  
Acetaminophen/Paracetamol may cause unreliable glucose sensor readings. If possible, 1519  
participants should avoid taking medications with acetaminophen while in Auto Mode. If 1520  
acetaminophen is taken, participants will be instructed to turn off auto mode and use BG meter 1521  
readings to follow glucose levels. Additional BG meter readings should not be used to calibrate 1522  
the sensor. Auto mode should be restarted when BG meter and CGM readings are consistently in 1523  
close agreement which may take up to  8-12 hours.  1524  
 1525  
Exclusionary medications are:  1526  
• Oral or parenteral glucocorticoids taken within 1 month prior to enrollment, or plans to take 1527  
oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term 1528  
oral or parenteral glucoc orticoids up to 7 days  1529  
• Any antidiabetic agents other than insulin  [ADDRESS_1185179] final study data.  1538  
 1539  
If participants wish to discontinue using the study devi ce without withdrawing, participant s will 1540  
be encouraged to remain in the study through the final study visit.  1541  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 59 OF 74 
  1542  
 Confidentiality  1543  
For security and confidentiality purposes, participants will be assigned an identifier that will be 1544  
used instead of their name. Protected health information gathered for this study will be shared 1545  
with the coordinating center, the Jaeb Center fo r Health Res earch in Tampa, FL.  De-identified 1546  
participant information may also be provided to research sites involved in the study.  1547  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 60 OF 74 
 
 Statistical Considerations  1548  
 1549  
 Statistical and Analytical Plans  1550  
The approach to sample size a nd statistical analyses are summar ized below. A detailed statistical 1551  
analysis plan will be written and finalized prior to the completion of the study. The analysis plan 1552  
synopsis in this chapter contains the framework of the anticipated final analysis plan.  1553  
 1554  
 Statistical Hypotheses  1555  
The co -primary outcomes are CGM -measured metrics over 12 -week periods ( excluding time 1556  
before auto mode is turned on) : 1557  
• Superiority in percent time >180 mg /dL (10.0 mmol/L) from 6AM to 11:59PM  1558  
• Non-inferiority in CGM -measured time <54 mg /dL (3.0 mmol/L) calculated over the full 24 1559  
hours of the day  1560  
 1561  
The study hypothes es can be stated as follows:  1562  
 1563  
Hyperglycemic Outcome:  1564  
• Null Hypothesis:  There is no difference in the percentage of time spent with sensor 1565  
glucose levels above 180 mg/dL between the two treatmen ts during the daytime  for the 1566  
entire study population .  1567  
• Alternative Hypothesis: There is a nonzero difference in the percentage of time spent 1568  
with sensor glucose levels above 180 mg/dL between the two treatments during the 1569  
daytime  for the entire study popu lation . 1570  
Hypoglycemic Outcome:  1571  
• Null Hypothesis:  There is a mean difference of at least 2% in the percentage of time spent 1572  
with sensor glucose levels below 54 mg/dL between the AHCL system and the 670G 3.0 1573  
system over the full 24 hours of the day for the entire study population.  1574  
• Alternative Hypothesis: There is a mean difference of less than 2% in the percentage of 1575  
time spent with sensor glucose levels below 54 mg/dL between the AHCL system and the [ADDRESS_1185180] deviation (SD) for time spent in [ADDRESS_1185181] a significant result (p < 0.05) to declare benefit of 1585  
the intervention. The two co -primary outcomes therefore do not inflate the type 1 error, but 1586  
requirin g both to be significant can inflate the type 2 error. A Bonferroni correction was 1587  
therefore applied to the power calculations by [CONTACT_852339] 2 error rate (i.e., 100% minus 1588  
power) for the two analyses. This represents a conservative estimate for compos ite power as the [ADDRESS_1185182] the null hypothesis.  1590  
 1591  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 61 OF 74 
 The total sample size was computed to be 65 for the following assumptions (1) 90% power, with 1592  
adjustment to account for the two co -primary analyses, (2) a 5% absolute reduction in time >180 1593  
mg/dL (10.0 mmol/L) with a standard deviation of paired differences of 12%, and a 2 -sided type 1594  
1 error rate of 5%, and (3) a non -inferiority limit of 2% for the treatment group comparison of 1595  
time <54 mg/dL (3.0 mmol/L) with an SD of paired dif ferences of 1.3% and 1 -sided type 1 error 1596  
of 2.5%.  [ADDRESS_1185183] 98% power.  [ADDRESS_1185184] -meal period is defined as follows: meal starts at the time the [ADDRESS_1185185] -meal period ends at three  hours after a meal unless  another 1607  
carbohydrate is entered   <[ADDRESS_1185186] -meal period.  1608  
 1609  
Hypoglycemia metrics are considered both safety and efficacy outcomes.  1610  
 1611  
The following co -primary outcomes will be compared between the two treatment arms in this 1612  
crossover trial (PID al gorithm vs. PID + Fuzzy logic algorithm):  1613  
• The percent time spent with sensor glucose >180 mg/dL (10.0 mmo l/L) during the day 1614  
(6AM – 11:59 PM)  1615  
• Non-inferiority for CGM time <54 mg/dL (3.0 mmol/L) over 24 hours  1616  
 1617  
The secondary efficacy analyses will include treatment comparisons for the following outcomes:  1618  
• CGM derived indices for the full 24 -hour day, during daytime (6AM -11:59PM), during 1619  
nighttime (12AM -5:59AM), and for each post -meal period : 1620  
o Mean glucose  1621  
o Coefficient of variation  1622  
o Percentage of senso r glucose from 70 to 180 mg/dL (3.9 to 10.0 mmol/L)  and 70 1623  
to 140 mg/dL  (3.9 to 7.8 mmol/L)  1624  
o Percentage of sensor glucose > 180 (daytime is a co -primary outcome) and >250 1625  
mg/dL (10.0 and 13.9 mmol/L, respectively)  1626  
o Peak glucose and change from the start of t he meal to the peak (only calculated [ADDRESS_1185187] -meal periods)  1628  
• Amount of total, basal and bolus daily insulin for the full 24 hour, daytime (6AM - 1629  
11:59PM), nighttime (12AM -5:59AM), and for each post -meal period  (both total units and 1630  
units/kg ). 1631  
• HbA1c  1632  
• BMI  1633  
 1634  
Additionally, summary statistics will be reported (but treatment arm comparisons will not be 1635  
done) for the following outcomes:  1636  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 62 OF 74 
 • CGM -derived indices over the first 84 days of each treatment period for 24 hours 1637  
(excluding time before auto mode is turned on ), daytime (6AM -11:59PM), n ighttime 1638  
(12AM -5:59AM), and for each post -meal period (meal star ts at the time the carbohydrate 1639  
is entered), measured for up to three  hours after a meal (or until another carbohydrate is 1640  
entered) : 1641  
o Percentage of sensor glucose <50 an d <60 mg/dL (2.8 and 3.3 mmol/L 1642  
respectively)  1643  
o Glucose area under the curve >180 mg/dL (10.0 mmol/L)  1644  
o Glucose area over the curve <70 mg/dL (3.9 mmol/L)  1645  
o Percentage of sensor glucose >300 mg/dL (16.7 mmol/L)  [ADDRESS_1185188] deviation  1647  
• Three level variables de noting change in total insulin, basal insulin, and bolus insulin 1648  
(increase by >10%, decrease by >10%, or in between)  1649  
• Binary HbA1c variables:  1650  
o Improvement ≥0.5% and ≥1.0%  1651  
o Relative reduction ≥10%  1652  
o Proportion of participants achieving HbA1c <7.0%  [ADDRESS_1185189] 80% of the time in both periods and who used the auto [ADDRESS_1185190] 80% of the time in both treatment periods, unless the N for the analysis 1665  
is >95% of the N in the p rimary intent -to-treat analysis.  1666  
 1667  
Safety  1668  
All participants will be included in safety analyses.  1669  
 1670  
 Analysis of the Primary Efficacy Endpoints  1671  
For each co -primary outcome, a single value will be calculated for each participant during each 1672  
period. Details regar ding the primary analysis cohorts, handling of missing data, and protocol 1673  
deviations are discussed in Section 10.5. Mean ± SD or percentiles appropriate to the distribution [ADDRESS_1185191] be significant based on these models.  1679  
 1680  
Time >180 mg /dL (10.0 mmol/L)  (superiority)  1681  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 63 OF 74 
 A 95% confidence inte rval will be reported for the difference between the two treatment arms  [ADDRESS_1185192] that a transformation will be necessary. A 1685  
two-sided p -value will be reported, and a 5% significance level will be used to declare statistical 1686  
significance.  1687  
 1688  
Time <54 mg/dL (3.0 mmol/L)  (non-inferiority)  1689  
A two -sided 95% confidence interval will be reported for the difference between the two [ADDRESS_1185193] squares model. Non -inferiority will be assessed by [CONTACT_23992] 1691  
the upper limit of this confidence interval to a non -inferiority limit of 2% (approximately 30 1692  
minutes per day). This limit was selected solely based on clinical judgment. The non -inferiority 1693  
limit corresponds to the difference between the 670G 4.0 AHCL system (which is the 1694  
experimental treatment) and the 670 G 3.0 HCL system (which is the active control). Residual 1695  
values will be examined for an approximate normal distribution. If values are highly skewed, 1696  
then a  transformation or nonparametric method will be used instead. A two -sided p -value will be 1697  
reported, and a 5% significance level will be used to declare statistical significance.  [ADDRESS_1185194] at alpha = 0.[ADDRESS_1185195] at 1701  
alpha = 0.025. Therefore, reporting a two -sided 95% confidence interval will provide flexibility [ADDRESS_1185196] for inferiority if non -inferiority cannot be declared while maintaining the overall type 1 1703  
error rate at 5%. Figure 4 below shows the inference to be drawn for various scenarios of the 1704  
two-sided 95% confidence interval:  [ADDRESS_1185197] as the co - 1717  
primary outcomes.  1718  
 1719  
Mean ± SD or percentiles appropriate t o the distribution for above secondary outcomes will be [ADDRESS_1185198] study visit.  Events will be separately listed in detail and tabulated for the pre - 1735  
randomization period  and each study period. Coding will use the Medical Dictionary for 1736  
Regulatory Activities (MedDRA) . 1737  
 1738  
In addition,  the following will be tabulated by [CONTACT_2939]: 1739  
• Number of adverse events / participants with at least one event  1740  
o Number of events meeting definition of ADE  1741  
• Number of serious adverse events /participants with at least one event  1742  
o Number of SAEs meeting definition of UADE  1743  
• Listing  of hospi[INVESTIGATOR_852311]  1744  
• Severe Hypoglycemic Events  1745  
o Number of severe hypoglycemic events as defined in the protocol /number of 1746  
participants with an event  1747  
o Number of severe hypoglycemic events associat ed with seizure or loss of 1748  
consciousness /number of participants with at least one event  1749  
• Diabetic Ketoacidosis  1750  
o Number of diabetic ketoacidosis events, as defined in the protocol /number of [ADDRESS_1185199] experienced any events in the 12 months prior 1761  
to enrollment as fixed effects adjusted in the model. All participants will be included in these 1762  
analyses.  1763  
 1764  
 Adherence and Retention Analyses  1765  
Tabulati ons and figures by [CONTACT_852340]:  1766  
• Flowchart showing any dropouts prior to and post randomization and treatment arm 1767  
completion  1768  
• Visit completion rates for each follow up visit  1769  
• Protocol deviations  1770  
• Numbers and reasons for unscheduled visits and phone calls  [ADDRESS_1185200] Operating Procedures 1779  
approximately every six months. The data to be reviewed will include information regarding 1780  
adverse events, device issues, and protocol adherence/deviations  as they may relate to participant 1781  
safety.  1782  
 1783  
 Sub-Group Analyses  1784  
Exploratory s ubgroup analyses/assessments of effect modification (interaction) will be 1785  
conducted for each of the two primary outcomes. Interpretation of the analyses will  be made with 1786  
caution, particularly in the absence of an overall difference . The general approach f or these 1787  
exploratory analyses will be to add an interaction term for the subgroup factor by [CONTACT_852341] 1788  
the model used for the primary analysis.  1789  
 1790  
The following baseline factors will be assessed:  1791  
• Age: as a continuous variable and in two age groups: 14 -<21 and 21 -<30 years old  1792  
• Baseline HbA1c: as a continuous variable and in two groups: HbA1c ≤8.5% and ≥8.6%  1793  
• Insulin method/CGM: 670G user, injection user with CGM, injection user with out CGM, 1794  
pump user with CGM, pump user without CGM  1795  
• T1D duration as a continu ous variable  1796  
• Sex 1797  
• Race/ethnicity  1798  
• Random C -peptide level  1799  
Beyond above assessment for interactions, the primary and secondary analyses also will also be 1800  
conducted separately in the two age groups and the two HbA1c groups, in addition to the CGM 1801  
metrics consid ered as safety outcomes. Analyses will only be replicated within these subgroups 1802  
for efficacy outcomes where p -values are being computed.  1803  
 1804  
 Multiple Comparison/Multiplicity  1805  
For the primary analyses, the intervention will be deemed effec tive only if the null hypotheses 1806  
for both co -primary outcomes are rejected. The type 1 error is therefore not inflated and there 1807  
will be no correction for multiple comparisons.  1808  
 1809  
For the secondary analyses, the false discovery rate will be controlled using the adaptive Two 1810  
Stage Benjamini -Hochberg procedure with <0.[ADDRESS_1185201] squares regression models as described for the co - 1822  
primary outcomes will be used to compare the percentage of time of CGM use and auto mode  1823  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 67 OF 74 
 use between the two periods. Monthly values for auto mode use and CGM use also will be 1824  
repor ted.  1825  
 1826  
 Analysis of Quality of Life Data  1827  
Quality of life  data collected during study assessments will be scored based on established 1828  
procedures and descriptive statistics (e.g., mean, range) will be calculated for each questionnaire 1829  
at each time point and a cross treatment groups. Similar models as described above for the 1830  
primary analysis will be used to compare the questionnaire scores between the two treatments.  1831  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 68 OF 74 
 
 Data Collection and Monitoring  1832  
 1833  
 Case Report Forms and Device Data  1834  
The main study data are collected through a combination of electronic case report forms ( eCRFs) [ADDRESS_1185202]. These documents should 1850  
be retained for a longer period, however, if required by [CONTACT_427]. No records will be 1851  
destroyed without the written consent of  the sponsor, if applicable.  It is the responsibility of the 1852  
sponsor  to inform the investigator when these documents no longer need to be retained.  1853  
 1854  
 Quality Assurance and Monitoring  1855  
Designated personnel from the Coordinating Center will be responsible for maintaining quality 1856  
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1857  
conducted and data are generated, documented and reported in compliance with the protocol, 1858  
Good Clinical Practice (GCP) and the applicab le regulatory requirements.  Adverse events will be 1859  
prioritized for monitoring.  1860  
 1861  
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 1862  
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 1863  
Investigations  – A Risk -Based Approach to Monitoring” (August 2013).  Study conduct and 1864  
monitoring will conform to 21 Code of Federal Regulations (CFR) 812.  [ADDRESS_1185203] importance for monitoring at the site are participant eligibility and adverse 1867  
even ts. Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1868  
monitoring will be performed in real -time with on -site monitoring performed to evaluate the 1869  
verity and completeness of the key site data. Elements of the RBM may include:  1870  
 1871  
• Qualification assessment, training, and certification for sites and site personnel  1872  
• Oversight of Institutional Review Board (IRB) coverage and informed consent 1873  
procedures  1874  
• Central (remote) data monitoring: validation of data entry, data edits/audit trail, pro tocol 1875  
review of entered data and edits, statistical monitoring, study closeout  1876  
• On-site monitoring (site visits): source data verification, site visit report  1877  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 69 OF 74 
 • Device accountability  1878  
• Communications with site staff  1879  
• Participant  retention and visit completion  1880  
• Quality control reports  1881  
• Management of noncompliance  1882  
• Documenting monitoring activities  1883  
• Adverse event reporting and monitoring  [ADDRESS_1185204] that it poses an increase in the risk to the participant, adversely affects the welfare, 1897  
rights, or safety of the research subjects, or negatively influences the scientific study integrity.  1898  
  1899  
Noncompliance with the clinical trial protocol, GC P, or procedure requirements may be either on 1900  
the part of the participant, the investigator, or the study site staff. As a result of deviations, 1901  
corrective actions may be developed by [CONTACT_3483].  1902  
 1903  
The site PI/study staff is responsib le for knowing and adhering to their IRB /EC requirements  for 1904  
reporting . Further details about the handling of protocol deviations will be included in the 1905  
monitoring plan.  1906  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 70 OF 74 
 
 Ethics/Protection of Human Participants  [ADDRESS_1185205]  1909  
The investigato r will ensure that this study is conducted in full conformity with Regulations for 1910  
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1911  
21 CFR Part 56, and/or the ICH E6.  [ADDRESS_1185206]  (IRB) (or Ethics Committee (EC))  1914  
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1915  
be submitted to the IRB /EC for review and approval.  Approval of both the protocol and the [ADDRESS_1185207] be obtained before any participant  is enrolled.  Any amendment to the 1917  
protocol will require review and approval by [CONTACT_1201] /EC before the changes are implemented to 1918  
the study.  All changes to the consent form will be IRB /EC approved; a determination will be 1919  
made regarding whether previously c onsented participants need to be re -consented.  1920  
 1921  
 Informed Consent Process  1922  
 Consent Procedures and Documentation  1923  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 1924  
the study and continues throughout the indivi dual’s study participation.  Extensive discussion of 1925  
risks and possible benefits of participation will be provided to the participants and their families.  1926  
Consent forms will be IRB /EC-approved and the participant will be asked to read and review the [ADDRESS_1185208] by [CONTACT_3486], their staff, 1943  
and the Coordinating Center(s) and their agents.  This confidentiality is extended to cover testing [ADDRESS_1185209] party without prior written approval of the Steering Committee.  1948  
 1949  
The study monitor, other authorized representatives of the Coordinating Center, representatives 1950  
of the IRB /EC or device company supplying study product may inspect all documents and 1951  
records required to be maintained by [CONTACT_093], including but not limited to, medical 1952  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 71 OF 74 
 records (office, clinic, or hospi[INVESTIGATOR_307]) for the participants in this study.  The cli nical study site will 1953  
permit access to such records.  1954  
 1955  
The study participant’s contact [CONTACT_3487] 1956  
internal use during the study.  At the end of the study, all records will continue to be kept in a 1957  
secure loc ation for as long a period as dictated by [CONTACT_606955] /national  1958  
regulations.  1959  
 1960  
Study participant research data, which is for purposes of statistical analysis and scientific 1961  
reporting, will be transmitted to and stored at the Jaeb Center for H ealth Research (JCHR) in 1962  
Tampa, FL , [LOCATION_003] . This will not include the participant’s contact [CONTACT_1290].  [ADDRESS_1185210] Transport Layer Security (TLS) technology. TLS [ADDRESS_1185211] architecture, which 1983  
places the database behind three different fi rewalls, where each firewall separates a tier : 1984  
• The internet to the web server;  1985  
• Web server to the application server;  1986  
• Application server to the database server. [ADDRESS_1185212] of long -term int ensified insulin 1990  
treatment on the development of microvascular complications of diabetes mellitus. The New 1991  
England journal of medicine. Jul 29 1993;329(5):304 -309. 1992  
2. Pi[INVESTIGATOR_9107] J. C. Insulin -pump therapy for type 1 diabetes mellitus. The New England journal 1993  
of medicine. Apr 26 2012;366(17):[ADDRESS_1185213], T. 1995  
Battelino. Use of continuous glucose monitoring in children and adolescents (*). Pediatr 1996  
Diabetes. May 2012;13(3):[ADDRESS_1185214], A. Ahmann, J. B. Buse, G. Dailey, S. N. Davis, C. 1998  
Joyce, T. Peoples, B. A. Perkins, J. B. Welsh, S. M. Willi, M. A. Wood. Effectiveness of sensor - 1999  
augmented insulin -pump therapy in type 1 diabetes. The New England journal of m edicine. Jul 2000  
22 2010;363(4):[ADDRESS_1185215], R. M. Bergenstal, K. M. Miller, S. N. DuBose, C. A. 2002  
Hall. The T1D Exchange clinic registry. The Journal of clinical endocrinology and metabolism. 2003  
Dec 2012;97(12):4383 -4389.  2004  
6. Mortensen H. B. Findings from the Hvidore Study Group on Childhood Diabetes: 2005  
metabolic control and quality of life. Horm Res. 2002;[ADDRESS_1185216] 1:[ADDRESS_1185217] century: an international comparison. Diabet 2009  
Med. Dec 15 2014.  2010  
8. Bergenstal R. M., D. C. Klonoff, S. K. Garg, B. W. Bode, M. M eredith, R. H. Slover, A. 2011  
J. Ahmann, J. B. Welsh, S. W. Lee, F. R. Kaufman. Threshold -based insulin -pump interruption 2012  
for reduction of hypoglycemia. The New England journal of medicine. Jul 18 2013;369(3):224 - 2013  
232. 2014  
9. Burdick J., H. P. Chase, R. H. Slover, K. Knievel, L. Scrimgeour, A. K. Maniatis, G. J. 2015  
Klingensmith. Missed insulin meal boluses and elevated hemoglobin A1c levels in children 2016  
receiving insulin pump therapy. Pediatrics. Mar 2004;113(3 Pt 1):e221 -224. 2017  
10. Steil G. M., K. Rebrin, C. Darwin, F. H ariri, M. F. Saad. Feasibility of automating insulin 2018  
delivery for the treatment of type 1 diabetes. Diabetes. Dec 2006;55(12):[ADDRESS_1185218], L. M. Huyett, J. B. Lee, H. C. Zisser, E. Dassau. Closed -loop artificial 2020  
pancreas systems: engine ering the algorithms. Diabetes Care. 2014;37(5):[ADDRESS_1185219], D. M. Nathan, E. R. Damiano. Outpatient glycemic control with a bionic 2023  
pancreas in t ype 1 diabetes. The New England journal of medicine. Jul 24 2014;371(4):313 -325. 2024  
13. Thabit H., A. Lubina -Solomon, M. Stadler, L. Leelarathna, E. Walkinshaw, A. Pernet, J. 2025  
M. Allen, A. Iqbal, P. Choudhary, K. Kumareswaran, M. Nodale, C. Nisbet, et al. Home  use of 2026  
closed -loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4 - 2027  
week, multicentre, randomised crossover study. The lancet. Diabetes & endocrinology. Sep 2028  
2014;2(9):701 -709. 2029  
14. Atlas E., R. Nimri, S. Miller, E. A. Grun berg, M. Phillip. MD -logic artificial pancreas 2030  
system: a pi[INVESTIGATOR_113440] 1 diabetes. Diabetes Care. May 2010;33(5):[ADDRESS_1185220] 2011;13(10):983 -990. 2033  
 
FLAIR  CLINICAL TRIAL PROTOCOL V7.1  2020 -03-17_CLEAN  PAGE 73 OF 74 
 16. Nimri R., I. Muller, E. Atlas, S. Miller, O. Kordonouri, N. Bratina, C. Tsioli, M. A. 2034  
Stefanija, T. Danne, T. Battelino, M. Phillip. Night glucose control with MD -Logic artificial 2035  
pancreas in home setting: a single blind, randomized crossover trial -interim analysis. Pediatr 2036  
Diabetes. Mar 2014;15(2):91 -99. 2037  
17. Nimri R. The DREAM CONSORTIUM: Integration of the MD -Logic into daily 2038  
management of diabetes. Paris, [LOCATION_009]: 8th Advanced Tech nologies and Treatments for 2039  
Diabetes; 2015.  2040  
18. Nathan D. M., M. Bayless, P. Cleary, S. Genuth, R. Gubitosi -Klug, J. M. Lachin, G. 2041  
Lorenzi, B. Zinman. Diabetes control and complications trial/epi[INVESTIGATOR_852312] 2042  
interventions and complications study a t 30 years: advances and contributions. Diabetes. Dec 2043  
2013;62(12):3976 -3986.  2044  
19. Kovatchev B. P., M. Breton, C. D. Man, C. Cobelli. In silico preclinical trials: a proof of 2045  
concept in closed -loop control of type 1 diabetes. J Diabetes Sci Technol. Jan 2009 ;3(1):44 -55. 2046  
20. Atlas E., R. Nimri, S. Miller, E. A. Grunberg, M. Phillip. MD -logic artificial pancreas 2047  
system: a pi[INVESTIGATOR_113440] 1 diabetes. Diabetes Care. May 2010;33(5):1072 -1076.  2048  
21. Nimri R., E. Atlas, M. Ajzensztejn, S. Miller, T. Or on, M. Phillip. Feasibility study of 2049  
automated overnight closed -loop glucose control under MD -logic artificial pancreas in patients 2050  
with type 1 diabetes: the DREAM Project. Diabetes Technol Ther. Aug 2012;14(8):728 -735. 2051  
22. Nimri R., T. Danne, O. Kordonour i, E. Atlas, N. Bratina, T. Biester, M. Avbelj, S. Miller, 2052  
I. Muller, M. Phillip, T. Battelino. The "Glucositter" overnight automated closed loop system for 2053  
type 1 diabetes: a randomized crossover trial. Pediatr Diabetes. May 2013;14(3):159 -167. 2054  
23. Philli p M., T. Battelino, E. Atlas, O. Kordonouri, N. Bratina, S. Miller, T. Biester, M. A. 2055  
Stefanija, I. Muller, R. Nimri, T. Danne. Nocturnal glucose control with an artificial pancreas at 2056  
a diabetes camp. The New England journal of medicine. Feb 28 2013;368(9 ):824 -833. 2057  
24. Ziegler C., R. Nimri, I. Muller, S. Klemencic, N. Bratina, S. Blasig, K. Remus, M. 2058  
Phillip, T. Battelino, O. Kordonouri, T. Danne, K. Lange. Reduced worries of hypoglycaemia, 2059  
high satisfaction and increased perceived ease of use after experi encing four nights of MD -Logic 2060  
artificial pancreas at home (DREAM 4). Journal of Diabetes Research. In Press 2015.  2061  
25. Nimri R., I. Muller, E. Atlas, S. Miller, A. Fogel, N. Bratina, O. Kordonouri, T. Battelino, 2062  
T. Danne, M. Phillip. MD -Logic overnight con trol for 6 weeks of home use in patients with type 2063  
1 diabetes: randomized crossover trial. Diabetes Care. Nov 2014;37(11):[ADDRESS_1185221]. Fully 2065  
automated closed -loop insulin de livery versus semiautomated hybrid control in pediatric patients 2066  
with type 1 diabetes using an artificial pancreas. Diabetes Care. May 2008;31(5):934 -939. 2067  
27. Buckingham B. A., R. W. Beck, K. J. Ruedy, P. Cheng, C. Kollman, S. A. Weinzimer, L. 2068  
A. DiMeglio,  A. A. Bremer, R. Slover, M. Cantwell. The effects of inpatient hybrid closed -loop 2069  
therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther. May 2070  
2013;15(5):401 -408. 2071  
28. O'Grady M. J., A. J. Retterath, D. B. Keenan, N. Kurtz, M. C antwell, G. Spi[INVESTIGATOR_307], M. N. 2072  
Kremliovsky, A. Roy, E. A. Davis, T. W. Jones, T. T. Ly. The use of an automated, portable 2073  
glucose control system for overnight glucose control in adolescents and young adults with type 1 2074  
diabetes. Diabetes Care. Nov 2012;35(11):2 182-2187.  2075  
29. de Bock M. I., A. Roy, M. N. Cooper, J. A. Dart, C. L. Berthold, A. J. Retterath, K. E. 2076  
Freeman, B. Grosman, N. Kurtz, F. Kaufman, T. W. Jones, E. A. Davis. Feasibility of Outpatient 2077  
24-Hour Closed -Loop Insulin Delivery. Diabetes Care. Nov 20 15;38(11):e186 -187. [ADDRESS_1185222]. Effectiveness of early intensive therapy 2080  
on beta -cell preservation in type 1 diabetes. Diabete s Care. Dec 2013;36(12):4030 -4035.  2081  
31. Grosman B., J. Ilany, A. Roy, N. Kurtz, D. Wu, N. Parikh, G. Voskanyan, N. Konvalina, 2082  
C. Mylonas, R. Gottlieb, F. Kaufman, O. Cohen. Hybrid Closed -Loop Insulin Delivery in Type 1 2083  
Diabetes During Supervised Outpatient Conditions. J Diabetes Sci Technol. Feb 15 2016.  2084  
32. Ly T. T., A. Roy, B. Grosman, J. Shin, A. Campbell, S. Monirabbasi, B. Liang, R. von 2085  
Eyben, S. Shanmugham, P. Clinton, B. A. Buckingham. Day and Night Closed -Loop Control 2086  
Using the Integrated Medtronic H ybrid Closed -Loop System in Type 1 Diabetes at Diabetes 2087  
Camp. Diabetes Care. Jul 2015;38(7):1205 -1211.  2088  
33. Garg SK, Weinzimer SA, Tamborlance WV, et al. Glucose outcomes in the in -home use 2089  
of a hybrid closed -loop insulin delivery system in adolescents and adults with type 1 diabetes.  2090  
Diabetes Technol Ther.  19(3):155 -163; 2017; doi:10.1089/dia.2016.0421.  [ADDRESS_1185223] WV, 2092  
Kaufman FR. Safety of a Hybrid Closed -Loop Insulin Delivery System in Patients With Type 1 2093  
Diabetes.  JAMA.  2016;316(13):1407 –1408. doi:10.1001/jama.2016.[ZIP_CODE].  2094  
35. Premarket Approval (PMA).” U S Food and Drug Administration Home Page, 28 Sept. 2095  
2016, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160017.   [ADDRESS_1185224] of continuous glucose 2098  
monitoring on glycemic control in adults with type 1 diabetes using insulin injections:  The 2099  
DIAMOND randomized clinical trial. JAMA 2017;317(4):371 -8. 2100  
37. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study 2101  
Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2102  
2008;359(14):[ADDRESS_1185225] of continuous glucose monitoring in well -controlled type 1 diabetes. Diabetes 2105  
Care. 2009;32(8):[ADDRESS_1185226] -BG: A randomized trial 2107  
comparing continuous glucose monitoring with and without routine blood glucose monitoring in 2108  
well-controlled adults with type 1 diabetes. Diabetes Care 2017; 40(4):538 -45. 2109  
 2110  
 2111  